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Antibiotic resistance (AR) is a serious growing threat around the globe. There 
has been no new antibiotic class developed in the past 30 years, while antibiotic-
resistant superbugs are emerging everywhere and becoming more and more life-
threatening. In 2019, AR pathogens took away about 35,000 lives and infected over 2.8 
million people a year in the United States alone. Experts predict that, by 2050, AR will 
be the top leading cause of death, claiming 10 million lives a year. 
Motivated and dedicated to thousands of families who lose their loved ones each 
year to antibiotic-resistant infections, our research lab studies the defense mechanisms 
of superbugs. Instead of finding a new antibiotic, we study how to remove their 
resistance using a potentiator called BPEI (branched polyethylenimine). BPEI is a 
chemical compound that can disable the resistance factors of superbugs while 
traditional antibiotics (i.e. amoxicillin) can now actively target the vulnerable 
pathogens. It is called “combination therapy”. My initial specific contribution is study 
to fight one of the most commonly clinical isolates of Staph infections—multidrug-
resistant Staphylococcus epidermidis. Previously known as a harmless commensal 
species on human skin, Staphylococcus epidermidis is now the first-ranking causative 
agent of hospital-related infections, with 24% mortality. It has become resistant to many 
antibiotics and thus acquired the name MRSE (Methicillin- Resistant Staphylococcus 
epidermidis). Additionally, MRSE bacteria can form dangerous biofilms – extra layers 
of self-made material – that protects them from antibiotics and helps them live on 
inanimate surfaces like medical devices for weeks to months. Persistent biofilms are 
also a leading cause of chronic wound infections. In the United States, a cost of $2 
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billion/year is estimated for S. epidermidis vascular-catheter-related bloodstream 
infections. This resistance is mainly governed by a protein called PBP2a, which the 
susceptible Staph bacteria do not have. The protein PBP2a has a very low affinity for 
traditional β-lactam antibiotics, thereby making first-choice antibiotics ineffective. 
Here, the use of BPEI becomes effective because exposure to BPEI molecules inhibits 
the function of PBP2a of MRSE, and therefore making them susceptible to existing 
antibiotics. 
Many experiments and analyses were conducted by using multiple biochemical 
techniques including microtiter plate assays, growth and time-killing curves, bacterial 
colony forming units, visible and fluorescence spectroscopies, electron microscopies, 
Fourier-transform infrared spectroscopy, and mass spectrometry. Not only being 
effective against MRSE, BPEI can also broaden antibiotic spectrum against other 
bacterial species like MRSA, Pseudomonas aeruginosa, E. coli and their biofilms. 
Exact concentrations of each combination treatment were found for each bacterial 
strain. New mechanisms of action of BPEI against different bacteria and its effects on 
human inflammatory responses were also elucidated and reported in this dissertation. 
Better understanding of how superbugs react to each treatment helps us to design more 
and more powerful potentiators. The efficacy of BPEI in combination therapy has 
shown to be effective against more than 20 clinical isolates (patients’ swab from 
OUHSC) of drug-resistant pathogens. This enables BPEI to function as a broad-
spectrum antibiotic potentiator which expands the opportunities to improve drug design 
(synthesis of BPEI analogs), antibiotic development, and therapeutic approaches (i.e. 
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Chapter 1: Staphylococcus epidermidis, an opportunistic pathogen 
Staphylococcus epidermidis is one of the most prevalent prokaryotic species on 
human skin and mucosal membranes that constitute the commensal flora. S. epidermidis 
has become one of the most common causes of primary bacteremia and healthcare-related 
biofilm infections. Infections are difficult to diagnose because the pathogen has natural 
niches on human skin and the ability to adhere to inanimate surfaces via biofilms. No 
antibiotic currently on the market can eradicate pathogenic biofilms, which contain 
complex defense mechanisms composed of slime-like extracellular polymeric substances 
(EPS). Alarmingly, S. epidermidis has acquired resistance to many antibiotics, which 
presents a danger to human health. Known as methicillin-resistant S. epidermidis 
(MRSE), most clinical isolates of MRSE in North America exhibit β-lactam resistance 
primarily due to the presence of mecA, a gene that bestows β-lactam antibiotic resistance 
in a manner similar to methicillin-resistant Staphylococcus aureus (MRSA). MecA 
encodes for expression of penicillin-binding protein 2a (PBP2a), which is absent in β-
lactam susceptible strains of S. epidermidis. Our research objective is to disable this 
resistance factor in MRSE with 600-Da branched polyethylenimine (BPEI). Cationic 
BPEI not only targets anionic wall teichoic acid (WTA), an essential cofactor for proper 
functioning of PBP2a, BPEI also reduces the EPS formation of MRSE biofilms rendering 
the bacteria vulnerable. We found that BPEI disables resistance in MRSE and potentiates 
β-lactam antibiotics against both planktonic and biofilm MRSE. Therefore, first line 
clinical treatments can be effective against MRSE infections when used in combination 
with 600-Da BPEI. This study also provides a better understanding to further extend the 
technology against other superbugs, which has been documented and published in the 
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Journal of ChemMedChem, ACS Biomacromolecules, ACS MedChem Letters, and ACS 
Infectious Diseases.1-5  
Antibiotic Resistance 
Antibiotic resistance (AR) is the ability of germs that overpowers the drugs 
intended to kill them. In 2013, the Centers of Disease Control (CDC) estimated around 2 
million people in the United States were infected with antibiotic-resistant germs and at 
least 23,000 Americans died each year. In a current update from the CDC’s Antibiotic 
Resistance Threats Report in 2019, that number has increased to almost 3 million cases 
infected with AR and 35,000 of them died.6 These numbers are only estimation in the US, 
a country with one of the best medicine and research technologies. Experts in the U.K 
predict that antibiotic resistance will be the top leading cause of deaths by 2050, which 
will kill 10 million lives a year, exceeding the number caused by cancer today. This 
alarming estimation would likely to come true unless a global response to the AR problem 
is initiated in time.7 Clearly, AR is already here. The challenges to antimicrobial 
discovery and optimization of novel drugs have lead AR become one of the greatest 
threats to global public health. Over the past three decades, there has been no successful 
discoveries of novel antibiotic classes naming the time as “the discovery void.” After the 
first antibiotic discovery of penicillin in 1928,8 a “golden age” of many new antimicrobial 
discoveries unexpectedly arose. Until 1960s, this process slowed down due to limited 
screening methods. The latest registered antibacterial class was the lipopeptides (i.e. 
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daptomycin) which was patented in 1987.9 A timeline of distinct antibiotic discoveries is 
adapted from Silver10 and shown in Figure 1 with their modes of action11-12 in Table 1. 
 
Figure 1. Antibiotic discovery timeline and the “discovery void.” Years shown are first 
reported patented antibiotics. 
 
Table 1. Distinct antibacterial drugs and their targets 
Antibiotic Class Mechanism Target Notes 
Penicillin 
β-Lactam 










Penams, β-lactamase resistant 
Penams, broad spectrum 
Penams, broad spectrum 
Penams, against Gram-negatives 



















Alternative to penicillin 




Chloramphenicol Chloramphenicol Broad spectrum, considered toxic 
Linezolid Oxazolidinone 







Broad spectrum, topical use 
Broad spectrum, against 
Pseudomonas 
Tetracycline Tetracycline 








Treatment of tuberculosis 
Norfloxacin 
Ciprofloxacin 
Fluoroquinolone DNA gyrase 
Broad spectrum, treatment of 












Topical use, against Pseudomonas. 








Since then, experimentation, innovation, and efforts for new antibacterial drugs 
have implemented, but little has reached clinical trials. The biggest reason for the 
discovery void is the withdrawal of pharmaceutical companies due to regulatory and 
scientific obstacles. Besides financial cost, a massive number of required standards and 
criteria that pharmaceutical companies must meet to develop an antimicrobial agent has 
shifted the investment equation towards other therapies. In many developing countries, 
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antibiotics are sold over the counter, and their use in livestock is poorly regulated. Lack 
of regulation can lead to overexposure, thereby encouraging acquired antimicrobial 
resistance. As the most common agricultural pathogens in developing countries, 
antibiotic resistance has another convenient means of spreading to humans.13 
On top of these challenges, the fitness of resistant mutants is yet another reason. 
Bacteria always find ways (fitness and mutations) to survive and defeat the drugs 
designed to kill them. Most of the life-threatening infamous superbugs belong to the 
ESKAPE pathogens: Enterococcus, Staphylococcus, Klebsiella, Acinetobacter, 
Pseudomonas, and Enterobacter species. These pathogens are commonly drug-resistant 
isolates which often lead to amputation or death once complications arise and no effective 
drugs are available.14 Not stopping at resisting conventional β-lactam antibiotics (i.e. 
ampicillin), they have made their way to resist all available classes of antibiotics including 
the drugs of last-resort (vancomycin and linezolid).15 Evidently, antibiotic resistance has 
been found in every country and every US state.6 The need for antibiotic resistance 
solutions is urgent. Each person, each organization, and each country can affect antibiotic 
resistance development. Even though there is no safe place from antibiotic resistance, 
actions can be taken to mitigate, slow down, and prevent it from disarming us especially 
with research and science.  
The Emergence of MRSE 
Staphylococcus epidermidis belongs to the Gram-positive Staphylococcus genus, 
which has a thick peptidoglycan cell wall. S. epidermidis is the most abundant 
microorganism among the human commensal microflora of the skin and mucosal 
membranes. Typically, around 10-24 different strains of S. epidermidis are carried by a 
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normal average person. Previously known as a harmless species, Staphylococcus 
epidermidis is now a frequent causative agent of nosocomial infections, along with 
Staphylococcus aureus.16 Because human skin characteristics (pH range, temperature, 
water/moisture, and nutrient contents) are widely different from person to person, their 
ability to adapt to a large range of environmental conditions make S. epidermidis an 
intrinsic opportunistic pathogen. With the widespread use of indwelling medical devices 
and implanted foreign bodies, as well as the rising number of immunocompromised 
patients,17 S. epidermidis has become a significant threat to the public health. In the U.S., 
S. epidermidis vascular catheter-related bloodstream infections create an economic 
burden of approximately $2 billion/year.18 Unlike the more aggressively virulent and 
coagulase-positive Staphylococcus aureus, S. epidermidis belongs to the coagulase-
negative staphylococci and is rarely a life-threatening infection outside of hospital 
settings. However, its prevalence in hospitals and the commensal lifestyle on human skin 
have granted S. epidermidis resilience against treatments.  
Complications in treatment are often due to the presence of specific antibiotic 
resistance genes and the production of biofilms (biofilms are agglomerations of bacteria 
enclosed in a protective matrix of extra-polymeric substances). S. epidermidis has been 
reported to colonize fabrics and abiotic surfaces, such as medical devices, for weeks to 
months.19 Polysaccharide intercellular adhesin, also known as poly-N-acetyl glucosamine 
(PIA/PNAG), was found to have a major function in S. epidermidis biofilm formation. 
PIA/PNAG is governed by the icaADBC operon, which appears more frequently in 
isolates of S. epidermidis from hospital-related infections than isolates from healthy 
individuals. As a permanent skin-colonizer, S. epidermidis may also have elaborate 
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mechanisms that allow it to attach to cardiac devices, surgical sites, central nervous 
system shunts, prosthetic joints, and vascular grafts.18-20 Resistance to certain antibiotics 
and disinfectants in many clinical isolates is due to the presence of selective-pressure-
exerted efflux quaternary ammonium compound (qac) genes found both in S. aureus and 
S. epidermidis.21-22 Encoding for efflux (or export) proteins, qac genes are responsible for 
antiseptic-resistance and are more prevalent in hospital/nursing environment due to the 
pressure of regular disinfectant/antiseptic usage. Additionally, mecA gene is found in all 
S. epidermidis isolates that are resistant to β-lactam antibiotics (methicillin resistance), 
therefore the name MRSE (methicillin-resistant Staphylococcus epidermidis) has 
emerged.23 
As the top leading cause, coagulase-negative staphylococci are responsible for a 
third of hospital-related bacteremia infections. S. epidermidis is the second most common 
cause of prosthetic valve endocarditis with 24% mortality, surpassed in frequency only 
by S. aureus.20 In orthopedic prosthetic device infections, S. epidermidis accounts for 30-
43% of cases. Inoculation of infections occurs at the time of surgery, and their infections 
usually stay indolent (symptoms of pain at the surgical site) without fever. Hospital 
isolates of S. epidermidis are methicillin resistant at significantly higher rates (75–90%) 
than S. aureus (40–60%).18 The emergence of MRSE infections emphasizes the need for 
antimicrobial drug design to yield new treatments before the pathogens become resistant 
to the last-resort antibiotics. 
The Cell Wall and The Gram Stain Characteristics 
Bacteria are single-cell prokaryotes which are chemically similar to eukaryotes 
with the compositions of carbohydrates, lipids, proteins, and nucleic acids. Mainly their 
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complicated cell walls and membranes structure and the absence of organelles make them 
distinct from eukaryotic cells. The bacterial cell wall is a complex structure that shapes 
the morphology of the cell. All prokaryotes have cell walls, except the Mycoplasma 
genus. The semirigid cell wall surrounds and protects the fragile cytoplasmic membrane 
and the interior of the cell from cytoplasmic osmosis and physical changes from their 
environment. The composition of the bacterial cell wall primarily has a macromolecular 
network of peptidoglycan, which consists of a repeating disaccharide of N-
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM). Rows of 10-65 linked 
NAG and NAM sugars form the “glycan” backbone. Polypeptides link adjacent glycan 
rows together and make up the “peptide” portion of peptidoglycan. The differences in the 
cell wall classify bacteria into two large groups: Gram-positive and Gram-negative 
(Figure 2), which was originally based on the technique of Gram-staining. The Gram stain 
procedure was invented by Han Christian Gram in 1884, and it is now one of the most 
useful techniques in microbiology to differentiate bacteria. Basically, Gram-positive 
bacteria have a thick multilayer of peptidoglycan and therefore will retain the purple color 
of a primary stain (crystal violet). On the other hand, Gram-negative bacteria can’t retain 
crystal violet after alcohol washing due to their thin monolayer peptidoglycan, and 




Figure 2. Cell wall structure of Gram-positive and Gram-negative bacteria. 
 Unique characteristics of the Gram-positive and Gram-negative bacteria are 
summarized in Table 2.11 In Gram-positive strains, the thick peptidoglycan layers 
compose the entire cell wall. Embedded within the peptidoglycan are the negatively 
charged teichoic acids (wall teichoic acids and lipoteichoic acids) which regulate the 
essential cations in and out of the cell. In Gram-negative bacteria, an additional outer 
membrane is present on top of their thin peptidoglycan monolayer. They do not have 
teichoic acids in the cell wall. The outer membrane consists of phospholipids, 
lipoproteins, and lipopolysaccharides (LPS), and it also provides an extra barrier to 
antibiotics, lysozyme enzymes (in tear, mucus, and saliva), and certain detergents. 
Between the peptidoglycan and the cytoplasmic membrane, periplasmic space (or 
periplasm) is a gel-like liquid containing many enzymes and transport proteins. Because 
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of their uniqueness, many antibiotics (β-lactams) target the bacterial cell walls by 
interfering with the peptide cross-linking of peptidoglycan. Consequently, the weaken 
cell wall would lyse due to rupture of fragile cell membrane, resulting in cell death. 
Table 2: Characteristics of Gram-positive and Gram-negative bacteria 
Characteristics Gam-positive Gram-negative 
Gram stain reaction (+) retain the purple 
color of crystal 
violet dye 
(-) does not retain crystal violet 
dye after a counterstain, safranin, 
decolorizes into pink  
Peptidoglycan layer Multilayer, thick Monolayer, thin 
Teichoic acid Present in most Absent  
Outer membrane Absent  Present  
Lipopolysaccharide  Absent  Present  
Toxins  Exotoxins Endotoxins 
Cell wall disruption 
by lysozyme  
Easy  Hard (due to outer membrane) 
 Most Gram-positive bacteria produce exotoxins—proteins that are metabolic 
products of cell growth. Exotoxins are highly toxic to hosts but usually heat-unstable and 
can be easily neutralized by antitoxins. Typical diseases caused by exotoxins are gas 
gangrene, scarlet fever, and tetanus. In contrast, endotoxins are primarily produced by 
Gram-negative bacteria.26 Endotoxins are the lipid A portions of the LPS of outer 
membrane. They are released when cells divide or lyse. Endotoxins have low toxicity 
compared to exotoxins, but they can withstand extreme heat (121°C) for an hour. They 
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are hard to be neutralized by antitoxins. Representative diseases by endotoxins are urinary 
tract infections and typhoid fever.  
β-Lactam Antibiotic Resistance  
In 1928, Alexander Fleming noticed a large fungal contamination on a petri dish 
of Staphylococcus aureus. The mold inhibited S. aureus colonies from growing. The 
incident led Fleming to the discovery of the first antiseptic drug, penicillin, which is 
named after the isolated fungus Penicillium notatum (later renamed as P. chrysogenum).27 
In March 1942, a near-death patient—Anne Miller—had blood poisoning (bacteria reach 
the bloodstream) and was administered experimental penicillin. She recovered in hours 
and became the first American saved by an antibiotic.6 Until the end of World War II in 
1945, penicillin finally made its way through commercialization, reached the general 
public, and saved millions of lives. Since then, a great number of penicillin-derivative 
antibiotics were developed: the β-lactams. All β-lactams have a core β-lactam ring in its 
chemical structure (Figure 3).  
 
Figure 3. A core chemical structure of penicillin with the β-lactam ring (square-shape 
ring in blue frame). The ring is a four-membered cyclic amide. It holds each bond at 90° 
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angle and is reactive to binding covalently to bacterial penicillin binding proteins 
(PBPs). 
 
Figure 4. Chemical structure of D-ala-D-ala peptidoglycan terminus, which has 
structural similarity to β-lactam ring.  
The β-lactam ring is a four-membered cyclic amide that is able to covalently bind 
to penicillin binding proteins (PBPs) within bacteria because the ring has a very similar 
structure to D-ala-D-ala terminus of the peptidoglycan (Figure 4). PBPs misrecognize β-
lactams for the serine transpeptidase catalytic site, and so their chemical interaction 
prevents transpeptidase enzymes (PBPs) from finishing the last stage of bacterial cell wall 
synthesis: crosslinking the peptidoglycan layers (Figure 5 and 6). The peptidoglycan 
plays a vital role for cell wall integrity, especially in Gram-positive bacteria. Without a 
strong cell wall, bacteria lyse and die from excessive cytoplasmic pressure. Antibiotics 
have saved a countless number of lives and are an important factor in raising the lifespan 
of humans over the past 80 years. However, evolution has its rules. Bacterial reproduction 
rate is extremely faster than human’s, and so is their mutation rate. In a given environment 
of antibiotic presence, bacterial fitness by natural and mutational selections favor the ones 
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survive and resist injurious drugs, leading to the emergence of more and more drug-
resistant pathogens. MRSE is one of them.  
In 2015, the US had 269.3 million antibiotic prescriptions given by healthcare 
providers, which is equivalent to 838 prescriptions per 1000 people. Among them, β-
lactams were the most popular prescribed antibiotics with amoxicillin top the chart at 171 
prescriptions per 1000 people.28 This rate isn’t going to change soon because today we 
depend heavily on antibiotics. From treatments of common illnesses (sinus/throat 
infections) to many medical advances (organ transplants, surgeries, and cancer therapies), 
we are dependent on antibiotics every day to fight bacterial infections before bacteria 
reach our blood and kill us. Despite how quick a new antibiotic drug was discovered; 
resistant germs were always identified after several years or even before the drug released 
to the market.29 Penicillin was first introduced to the public in 1943, but penicillin-
resistant Staphylococcus was found in 1940. Methicillin was discovered in 1960, and 
shorty after in 1962 methicillin-resistant Staphylococcus was identified. Today, almost 
90% of all hospital isolates of Staphylococcus epidermidis are methicillin-resistant 
(MRSE). The staphylococcal cassette chromosome mec (SCCmec) is the root of 
methicillin resistance. SCCmec contains mecA gene which is eventually translated into 
PBP2a proteins that are resistant to β-lactams. In S. epidermidis, ten different structures 
of SCCmec were found, in which SCCmec type IV element was the most common and 
the most problematic. SCCmec type IV can be acquired and spread without the presence 
of antibiotic pressure.18 This SCCmec is also found to be a one-way horizontal gene 




Figure 5. Illustration of the cell wall peptidoglycan crosslinking in MRSE. Penicillin 
binding proteins (PBPs and PBP2a) crosslink the subunits of the peptidoglycan, 
completing the last stage of cell wall synthesis. 
 
Figure 6. Illustration of β-lactam resistance factor, PBP2a, in MRSE. Regular PBPs are 
inhibited by β-lactam antibiotics, except PBP2a. PBP2a has low affinity to β-lactams 
and thereby can still crosslink the cell wall without being affected. A cofactor of PBP2a 
is the wall teichoic acid (WTA) which localizes PBP2a. 
In addition to the SCCmec, the second most important determinant for MRSE’s 
invasiveness is the intercellular adhesion ica genes that regulate poly-N-
acetylglucosamine (PNAG) production.31-32  As the main component of the protective 
biofilm’s exopolymer substances (EPS), PNAG has a pivotal role in S. epidermidis 
biofilm formation and immune evasion in vitro and in vivo. The regulation of PNAG 
production is less well understood, and some reports on the necessity of PNAG in biofilm-
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forming bacteria are contradictory.18, 33 However, the biofilm EPS has been found to 
protect S. epidermidis from host immune defense molecules, antimicrobial peptides 
(AMP), and antibiotic attack.34-35   
The Need for New Strategies 
Drug development takes at least a decade to get FDA approval and reach the 
market. The process first starts in the laboratory where new discovery occurs, and if the 
discovery is promising then many following steps will proceed: preclinical research 
(efficacy and safety on animal models), then clinical phase 1, phase 2, and phase 3 (on 
human volunteers). Each step can take from 1 to 4 years and can cost millions of dollars. 
With this costly and time-consuming process, there are clearly too few antibiotics to meet 
patient demands. Besides that, natural and acquired drug-resistance via horizontal gene 
transfer in bacteria indeed add up to the urgent need for new strategies. Alternative 
treatments that combine existing drugs with potentiators have become a topic of interest. 
Potentiators remove the resistance or restore the susceptibility of pathogens, while 
antibiotics attack the vulnerable germs. These strategies can potentially be as effective as 
new antibiotics because they have lower risk and quicker development process.  
As a ubiquitous commensal species of the human microflora, opportunistic S. 
epidermidis carry an optimum reservoir pool of genetic information (including the 
methicillin resistant gene SCCmec) that is ready to express and spread to other bacteria 
at any time. Hundreds of thousands of Americans are infected with MRSE each year, 
especially patients with prosthetic devices or intravenous catheters. With a dwindling 
arsenal of new antibiotics, we are motivated to combine existing antibiotics with 
potentiators (low-molecular weight branched polyethylenimine, Chapter 2.) and re-
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evaluated as combination treatments against multidrug-resistant superbugs: MRSE, 
MRSA, and Pseudomonas aeruginosa.  
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Chapter 2: 600-Da Branched Polyethylenimine (BPEI) and Its Effect 
on Human Inflammatory Responses 
Background 
Polyethylenimine (PEI) or also known as polyaziridine is a polymer of repeating 
units of an amine group and an ethyl spacer. PEI was first commercially produced in 
1938 by a chemical company Badische Anilin und Soda Fabrik in Germany and by 
Chemirad Corporation in the US.36 Its linear form contains only secondary amines with 
a chemical formula of (C2H5N)n and is solid at room temperature. Branched PEIs, on the 
other hand, can contain primary, secondary, and tertiary amine groups and are viscous 
liquids at room temperature. PEIs are mainly obtained by homopolymerization of 
aziridine (saturated three-membered cyclic compound including one nitrogen and two 
carbons) and are available in different molecular masses. PEIs are useful in many 
applications including the manufacturing of paper, textile, adhesives, detergents, and 
cosmetics. In biochemical research, scientists have found valuable roles of PEIs for 
tissue culture and gene delivery.37-39 Almost all documented reports focused on large-
molecular PEIs ( > 10000 Da), while the lower molecular weight PEIs (< 2000 Da) are 
less cytotoxic and less well understood. Our lab started studying PEIs as metal-
interfering agents in bacteria and accidentally discovered their abilities to restore 
susceptibility to antibiotic-resistant bacteria, especially the branched polyethylenimines 
(BPEI).40-41 This finding laid the foundation and shifted our research into combinational 
treatments against multidrug-resistant pathogens (Staphylococcus aureus, 
Staphylococcus epidermidis, and Pseudomonas aeruginosa) using low-molecular 
weight BPEI (the 600-Da or unless otherwise noted). This chapter summarizes BPEI’s 
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chemical characteristics, cytotoxicity, and its effects on inflammatory responses of 
human epithelial keratinocytes. 
Chemistry and Applications of BPEI  
Polyethylenimine (PEI) can be synthesized from 300 to 106 Da using different 
alkylating agents during ring opening of polymerization of aziridine. The amine 
distribution (primary/secondary/tertiary) or the branching of BPEI can also be obtained 
by special techniques (addition of acids and reactants).37, 42 600-Da BPEI used in our 
research was purchased from PolysciencesInc which has a ratio of 
primary/secondary/tertiary amines of 1/2/1 (Figure 7). It’s highly branched polymer 
with roughly spherical shape. BPEI is miscible in water. In aqueous solution, primary 
amines of BPEI are protonated at neutral pH, making the solution cationic. 
 
Figure 7. Chemical structure of 600-Da BPEI. The repeating unit of an amine group 
and an ethyl 2-carbon spacer continues on for larger molecular-weight BPEIs. 
 
PEIs are used primarily in manufacturing a variety of products.37 PEIs have been 
used in the paper industry for decades as retention and drainage agents. Today, the 
rising of paper recycling industry makes PEIs more important fixing agents for 
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flocculating contaminants. In the coating industry, PEIs are used in a variety of coating 
purposes: tie-coat adhesives, laminated films, primers, pigment dispersants, and amine 
components of epoxy resins. PEIs are also used as chelating agents of heavy metals like 
zinc and copper, and as metal surface brighteners for galvanic baths. In water treatment 
applications, PEIs are used as clarifying aids. PEIs are also used in air purification as 
absorbents of ozone and acidic gas molecules. In textile industry, PEIs are used as dye-
fixation agents and to reduce static properties of fabric. In biological research, cationic 
PEIs have attracted great attentions in gene therapy and hence opened up a myriad of 
therapeutic opportunities. Extensive studies have investigated and concluded that the 5-
25 kDa BPEI as the most suitable candidates for gene delivery due to high cellular 
uptake, great solubility in water, good transfection, and inexpensive synthesis. Less 
effectively, low-molecular-weight BPEI (<2000 Da) loses their charge density to 
compact and protect the genetic material.39 
600-Da BPEI’s Cytotoxicity and Biocompatibility 
In a biological system, low toxicity is required for any applications, especially 
on the human body. Despite their high transfection efficiency, in vitro cytotoxicity of 
PEIs appears to increase with increasing polymer size, remaining a challenging issue 
clinically.38-39, 43-44 However, documented studies only tested relatively large PEIs (10-
25 kDa) because they are the most effective in gene therapy. Deviated from the large 
interest, we focus on using the smallest commercially available BPEIs in combination 
antibiotic therapy against difficult-to-treat bacterial infections where the high charge 
density of large-sized BPEI is not needed. Therefore, our lab examined the cytotoxicity 
of 600, 1200, 1800, and 10000-Da BPEIs on human cell lines.45 The results suggested 
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that the smallest (600-Da) BPEI could be the lead potentiator for combination antibiotic 
treatments. 600-Da BPEI had the lowest in vitro cytotoxicity with the IC50 of 1090 and 
690 µg/mL on human HeLa cells and HEK293, respectively. The IC50 of 10000-Da 
BPEI was much smaller: 6.6 and 1.9 µg/mL on HeLa cells and HEK293 cells, 
indicating a more cytotoxicity than 600-Da BPEI. Additionally, lactate dehydrogenase 
(LDH) assays showed that 600-Da BPEI gave the lowest nephrotoxicity of 3.5% at 63 
µg/mL (even lower than Polymyxin E/Colistin which was >20% nephrotoxicity at the 
same concentration tested).45 These data highlight the safety of 600-Da BPEI on human 
cell lines as it is the lowest cytotoxic BPEI that’s commercially available. Low-
molecular-weight BPEI’s biocompatibility has been reported with the highest tolerance 
on dermal applications.46 Thus, 600-Da BPEI is chosen to be the lead potentiator in our 
studies for coupling with existing antibiotics against antibiotic-resistant pathogens as a 
promising therapeutic agent.  
Purpose of Experiment 
The purpose of this experiment is to characterize 600-Da BPEI using 
instrumental analyses—high performance liquid chromatography (HPLC), mass 
spectrometry (MS), and Fourier-transform infrared spectroscopy (FTIR)—and to 





High Performance Liquid Chromatography (HPLC) 
Mobile phase: A ratio of acetyl nitrile (ACN): water: phosphoric acid = 10:90:0.1 was 
used to make the mobile phase by mixing them with their respective volumes of 100mL 
of ACN, 900 mL of water, and 1mL of H3PO4. The pH was 3.5. 
Chromatographic conditions: Flow rate: 1.0 mL/min; Wavelength: 260nm; Injection 
Volume: 15 µL; Column: ODS-AQ C18, S-5 micron, 120 Angstrom, (4.6 x 250mm) 
The purity of 600-Da BPEI stock solution (2.56 mg/mL) was measured using a 
DIONEX HPLC with UVD340U, ASI 100, and P680 Pump. 
Mass Spectrometry (MS) 
600-Da BPEI sample (1mg/mL) was made using HPLC-graded water as solvent. 
The sample (2µL) was injected using Waters Acquity M-Class refrigerated (4°C) 
autosampler and UPLC with methanol as the isocratic mobile phase at 20.0 µL/min. 
The sample was introduced into a Waters SYNAPT G2-Si Q-TOF Mass Spectrometer 
equipped with an electrospray ionization (ESI) source in positive mode. Nitrogen was 
used as a nebulizing and a drying gas with a capillary voltage of 3.20 kV. Data were 
collected and analyzed with MassLynx (V4) software. 
 Fourier-transform infrared spectroscopy (FTIR) 
 600-Da was deposited on a KBr salt plate using CCl4 solvent. BPEI’s spectra 
were collected using a Bruker Tensor II FTIR spectrometer equipped with attenuated 




Effects of BPEI on human epithelia’s inflammatory cytokines 
Materials: HEKa cells (primary human epithelial keratinocytes; Invitrogen), 
Epilife Medium and growth supplement (Invitrogen), lipopolysaccharides 
from Escherichia coli O111:B4 (Sigma), peptidoglycan from Staphylococcus aureus 
(Sigma), and Human (IL-8/CXCL8, IL-6, TNF-alpha, IL-1 beta/IL-1F2) Quantikine 
ELISA Kits (R&D). 
Methods: HEKa cells were seeded in T-75 tissue culture flasks with Epilife 
media supplemented with human keratinocyte growth supplement 100ug/mL and 100 
U/mL of pen/strep and incubated at 37°C in a CO2 incubator. Fresh media was replaced 
every 2 days. Until the cell confluence reach 80-90%, they were split into a new 
passage. To avoid cell senescent, all experiments were performed with cells at passage 
3-7. HEKa cells were cultured in a new 24-well plate until 80-90% confluence (total V 
= 1mL/ well). Then treatments of 600-Da BPEI (64, 128, 256, 512, and 1024 µg/mL), 
LPS (lipopolysaccharide from E. coli; 5 µg/mL), PG (peptidoglycan from S. aureus; 5 
µg/mL) were added in triplicate cultures for 24 hr. The cell media was collected in 1.5 
mL Eppendorf microtubes and stored at -20°C until ELISA assays were performed. 
Concentrations of IL-8, IL-6, TNF-α cytokines released into the media were quantified 
followed the instructions of Quantikine Colorimetric ELISA assay kits (R&D Systems). 
Absorbance was measured at 450 nm and 570 nm. Final corrected absorbance was the 
subtraction at 450 nm from the one at 570 nm.  
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Results and Discussion 
Instrumental Analyses 
Instrumental analysis is an important and powerful method in analytical 
chemistry for obtaining qualitative and quantitative data about the structure and 
composition of matters. For a better understanding of the chemistry itself as well as 
laying a foundation for future BPEI-derivative syntheses, 600-Da BPEI was 
instrumentally analyzed using HPLC, MS, and FTIR.  
Chromatography is a sophisticated technique that has applications in all shape 
and size of science, and high-performance liquid chromatography (HPLC) is one of the 
most popular separation techniques by using a liquid mobile phase. The working 
principle of HPLC can be described as a mass transfer process with the adsorption of 
the analytes to a column filled with adsorbent. The interactions are based on 
hydrophilic, hydrophobic, dipole-dipole, ionic, or the sum of all in which are influenced 
mostly by different stationary phase, mobile phase, pH, temperature, pressure, and flow 
rate. A peristaltic pump drives both solvent and sample through a column, which is the 
stationary phase, where separation takes place. Right after the column, a detector 
detects those separated species and displays on computerized charts.47-48 Here, 600-Da 
BPEI solution used in all testing was run through a reverse-phase HPLC to determine its 
purity as well as its retention time in the non-polar column used. As shown in Figure 8, 
the peak at 2.09 min indicates that the BPEI solution was highly pure (single peak) and 




Figure 8. HPLC chromatogram of 600-Da BPEI solution (2.56 mg/mL). Retention time 
of BPEI peaks at 2.09 min. 
Characterization of the BPEI molecule was further examined using a Q-TOF 
(quadrupole-time-of-flight) mass spectrometry (MS), one of the most sophisticated 
instruments for accurate mass-to-charge-ratio (m/z) characterization. As shown in 
Figure 9, 600-Da BPEI fragmentation gave most of its abundant ionized peaks at around 
500 m/z. A common difference of 43 m/z exists between one peak to the adjacent 
another, indicating the repeating unit of the polymer tested BPEI: an amine plus an 
ethyl group. This repetitive pattern confirming the purity and polymerized chemical 





Figure 9. Mass spectrum of 600-Da BPEI. Most abundant peaks are around ~500 m/z 
which are the most ionized fragments of 600-Da BPEI. Most peaks have a similar 
difference of 43 m/z from their adjacent peaks, which is equal to the m/z ratio of one 
amine and an ethyl repeating unit of the polymer BPEI (i.e. 534.5 – 491.5 = 43 m/z). 
Functional groups of BPEI were captured by Fourier-transform infrared 
spectrometry, which is a technique used to measure a transmittance of a sample over a 
wide spectral range.  Because different functional groups have different chemical 
structures which absorb or transmit different frequencies. Therefore, they can be 
determined and analyzed by a FTIR. Figure 10 shows a FTIR spectrum of the 600-Da 
BPEI. The broad peak at 3300-3500 cm-1 indicate the N-H bond of the amines. The 
strong peaks at 2935, 2860, and 1467 cm-1 are from alkane C-H stretches of the alkyl 
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spacers. Carbon C-C bonds throughout the polymeric chain are indicated with the 1641 
and 1566 cm-1. The moderate peak at 1311 cm-1 confirms the C-N bond.  
 
Figure 10. FTIR spectrum of 600-Da BPEI (in CCl4) 
Overall, chemical properties of our lead potentiator BPEI have been 
instrumentally characterized: purity, polarity, ionized fragments, and functional groups. 
These data are reported for future use as a helpful foundation knowledge to modify or 
synthesize BPEI-derivatives.  
Inflammatory Response of Human Epithelial Keratinocytes exposed to BPEI 
The innate immune system is one of the first-line defense mechanisms in the 
human body, especially in wound healing. As one of the most complex biological 
events, wound healing involves many interactive processes mediated by local resident 
cells (keratinocytes, fibroblasts, nerve cells) and infiltration of neutrophils, mast cells, 
macrophages, and lymphocytes to trigger production of growth factors and cytokines.49 
Cytokines are chemical messengers produced by all immune cells for their 
communication. Interleukins (ILs) are those serve for leukocyte communication. The 
activation and suppression of immune system or cell division are closely related to 
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interleukins. For example, interleukin IL-6 functions in proliferative phase of healing. 
IL-6 was found with significantly elevated amount in chronic wounds compared to 
acute wounds,50 suggesting the inflammatory phase is likely stuck in chronic wound 
healing process. Chemokines are a group of cytokines that are responsible for leukocyte 
recruitment into sites of infection or injury and for maintenance of inflammatory 
reaction, with the best known is IL-8 (or CXCL-8).51 Peak levels of IL-8 are often 
caused by neutrophils and found under a wound surface. Another subgroup of cytokines 
is tumor necrosis factors (TNFs), which mainly activate immune cells to sites of 
infection and to tumor cells to destroy them. TNFs are cytotoxic specifically to tumor 
cells, with TNF-α is the most outstanding member in having many physiologic 
functions including the survival and death of other cells. Expression of proinflammatory 
cytokine TNF-α also induces the production of other cytokines (IL-1, IL-6, and IL-8) 
that increase the inflammatory responses of leukocytes.11, 52 
Bacterial products, such as cell wall component lipopolysaccharides (LPS) or 
peptidoglycan (PG), also stimulate recruitment and activation of phagocytes. These 
foreign products are grouped into pathogen-associated molecular patterns (PAMPs). 
PAMPs are recognized by toll-like receptors (TLRs) which eventually leads to secretion 
of cytokines IL-6, IL-8, and TNF-α in response to inflammation reactions. Large scales 
of these inappropriate cytokine productions may cause even more diseases: autoimmune 
diseases (i.e. rheumatoid arthritis and systemic lupus erythematosus), chronic wound 
infections, and autoinflammatory diseases (asthma and arthritis).53-54 Therefore, a good 
topical anti-bacterial agent must not induce inflammation itself. Here, inflammatory 
responses of human epithelial keratinocytes (IL-8, IL-6, and TNF-α) after being 
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exposed to 600-Da BPEI for 24 hours were collected and measured using ELISA 
assays. Standard curve of each cytokine was graphed and is shown below (Figure 11). 
Standard fitted equations were found with strong correlation coefficient, R-squared 
values (all 3 R-squared are > 0.99). These equations were then used to calculate the 
amounts of cytokines released by HEKa cells. For IL-8, cell culture supernates were 
diluted 10x before added to the ELISA kit. For IL-6 and TNF-α, no dilutions were made 




Figure 11. Standard curves of the three cytokines tested (IL-8, IL-6, and TNF-α). 
Linear fitted equations are shown with their corresponding R-squared values. These 




As a result, 600-Da BPEI caused a minimal release of all three cytokines tested 
by HEKa cells. As shown in Figure 12, the amount of each cytokine produced is 
reported in picograms pg/mL. The only significant difference in responses compared to 
the untreated control is by peptidoglycan (PG) from S. aureus and by 
lipopolysaccharide (LPS) from E. coli. Variety of BPEI concentrations (64 – 1024 
µg/mL) showed no significant changes in the three cytokine responses. Interleukin IL-8 
was found to be the highest concentrations released (>1500 pg/mL by PG/LPS and 
~200 pg/mL in untreated control). IL-6 was found to be in smaller amounts (~350 
pg/mL by PG/LPS and <50 pg/mL in untreated control). The lowest-concentration 
cytokine found was TNF-α (~30 pg/mL by PG/LPS and <10 pg/mL in untreated 
control). Larger error bars in the IL-6 and TNF-α graphs were due to the smaller in 
absorbance intensity that was close to a detection limit. Nevertheless, statistical 
analyses using t-test (95% confidence) indicate significant differences of these 






Figure 12. Cytokines released (picograms - pg/mL) by human epithelial keratinocytes 
(HEKa cells) in responses to peptidoglycan (PG), lipopolysaccharides (LPS), and 600-
Da BPEI. Data shown the average of triplicate trials. Error bars denote standard 
deviation. (*) indicates significant difference found between that sample and the 
untreated control (t-test, p-value < 0.05). 
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Therapeutic Potentials of 600-Da BPEI 
Staphylococci are notorious for their skin and soft-tissue infections that often lead 
to more complicated diseases. Each year, millions of acute skin and soft tissue 
infections (SSTIs) become chronic wound infections.55-58 Instead of taking 3-6 weeks to 
heal, chronic wounds persist for 3-6 months. Delays in healing acute SSTIs are often 
due to a prolonged inflammatory phase of healing caused by bacterial debris, such as 
peptidoglycan from S. aureus, which is a PAMPs molecule. Inappropriate expression of 
cytokines caused by PAMPs can trigger toxic shock and blood poisoning or sepsis. 
Over production of these chemical messengers provokes the immune system to “panic”, 
and destructive self-harm will be the consequence of an autoinflammation and 
prolonged chronic wound healing. Therefore, stopping PAMPs from triggering the 
release of inflammatory cytokines can theoretically restore optimal immune response. 
However, bacterial metabolic products including exotoxins and endotoxins are 
inevitably difficult to prevent. Not many successful antibacterial drugs are anti-
inflammation. Fortunately, 600-Da BPEI can meet both criteria (more details in Chapter 
6).  
 In short, BPEI is considerably safe with low in vitro toxicity,45 doesn’t cause 
cytokine release (Figure 12), prevents cytokine triggering by PAMPs, and has 
antibacterial and antibiofilm-potentiation potentials against MRSE, MRSA, and P. 
aeruginosa (the following chapters). Additionally, BPEI electrostatically binds Gram-
positive and Gram-negative cell wall components (teichoic acid/PG and LPS). Thus, 
this interaction with BPEI can possibly decrease the inflammatory cytokine release 
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caused by these pathogens, which highlights excellent therapeutic potentials of BPEI for 
antibiotic-resistant treatment as well as for acute and chronic wound care. 
Conclusions 
Characterization of BPEI using instrumental analyses has been documented, 
laying a background foundation for future BPEI-analogs’ synthesis and characteristic 
comparison. Inflammatory responses by human epithelial keratinocytes exposed to 
BPEI shows significantly lower amount than those exposed to bacterial debris PG and 
LPS. Therefore, more therapeutic potentials could be explored using BPEI, especially as 





Chapter 3: Synergy between β-lactam antibiotics and BPEI against 
planktonic MRSE 
Background 
From a comparative epidemiology study in Belgium,59 S. epidermidis isolates 
from catheter-related bloodstream infections (CRBSI) were found to have significant 
resistance to more antibiotics than the commensal isolates. More than 75% of the CRBSI 
isolates contained the resistance gene mecA, while only 3% of the S. epidermidis isolates 
from healthy individuals did. Additionally, the majority of the MRSE isolates are resistant 
to multiple antibiotics including oxacillin, erythromycin, and ciprofloxacin.59 S. 
epidermidis is involved in hospital-acquired infections60 which pose a great danger to 
public health. We were motivated to better understand the pathogenesis of MRSE as well 
as the pharmacology of antibiotics in combination with 600-Da branched 
polyethylenimine (BPEI) against S. epidermidis laboratory strains and clinical isolates. 
Our lab previous research started to use BPEI to restore susceptibility to methicillin-
resistant S. aureus (MRSA) after an accidental experiment happened in 2014. At the time, 
a former student was examining how metal binding/blocking by BPEI affects bacteria. 
Unexpectedly, chloramphenicol-resistant Bacillus subtilis treated with chloramphenicol 
and BPEI resulted in death, therefore laying the foundation for subsequent projects with 
antibiotic potentiation against drug-resistant pathogens.41  
β-lactam antibiotics (i.e. amoxicillin) are first-line drugs that inhibit bacterial cell 
wall synthesis by irreversibly binding to the penicillin-binding proteins (PBPs), a 
subgroup of enzyme transpeptidases. β-lactam binding to PBPs prevents them from 
crosslinking the cell wall peptidoglycan. Without cell wall synthesis, bacteria are unable 
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to replicate and consequently die. However, MRSE has the staphylococcal cassette 
chromosome mec (SCCmec), which contains the gene mecA. MecA is ultimately 
translated to create PBP2a, a unique penicillin-binding protein that has a low affinity for 
β-lactam antibiotics relative to other PBPs, thereby making these first-choice antibiotics 
ineffective.[3] In our study, we disabled this resistance factor using 600-Da BPEI, a low-
molecular-weight cationic polymer. Data show that a combination of BPEI and β-lactam 
antibiotics kills MRSE. The proposed mechanism of action is that BPEI electrostatically 
binds to wall teichoic acid (WTA), which is an anionic polymer in the cell wall of S. 
epidermidis and other Gram-positive bacteria (Figure 13).  
 
 
Figure 13. Illustrations of cell wall peptidoglycan in MRSE. PBPs crosslink the 
peptidoglycan subunits finishing the last stage of cell wall synthesis unless inhibited by 
β-lactams. MRSE’s methicillin-resistant factor is the extra PBP2a, which is not affected 
by β-lactams.  600-Da BPEI binds WTA and blocks PBP2a’s localization, thereby 




WTA has been suggested to play an important role in the localization of penicillin binding 
proteins, especially PBP2a.61 Foxley et al. successfully potentiated β-lactams against 
MRSA by targeting WTA with BPEI.45 A similar mechanism of action is hypothetically 
believed to exist between BPEI and β-lactams against MRSE. Thus, when BPEI binds to 
WTA, PBP2a loses its ability to function, and MRSE’s susceptibility to β-lactams is 
restored. 
Purpose of Experiment 
The purpose of this experiment is to determine the efficacy of BPEI in 




 Staphylococcus epidermidis bacteria were purchased from the American Type 
Culture Collection (MRSE ATCC 29887: methicillin-resistant, MRSE ATCC 35984: 
methicillin-resistant, and MSSE ATCC 12228: methicillin-susceptible). Two clinical 
isolates of MRSE were provided by Cindy McCloskey, M.D. from the University of 
Oklahoma College of Medicine. Chemicals were purchased from Sigma–Aldrich 
(DMSO, growth media, and electron microscopy fixatives). Antibiotics were purchased 
from Gold Biotechnology. 600-Da BPEI was purchased from Polysciences. 
In vitro Checkerboard Assays 
 Checkerboard assays were conducted to identify synergy between 2 drugs 
combined (BPEI and antibiotics) against bacteria. Briefly, stock solutions of oxacillin, 
ampicillin, amoxicillin, linezolid, and vancomycin were made in DMSO. Antibiotic 
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solutions were serial diluted and added to pre-sterilized 96-well plates so that the final 
DMSO concentration was less than 1%. A stock culture was made of one colony per 1 
mL and added 1% v/v to cation-adjusted Mueller–Hinton broth (MHB) in the 96-well 
plates. Optical density readings at 600 nm (OD600) were made using a Tecan Infinite 
M20 plate reader immediately after inoculation. The plates were incubated for 24 hr at 
35°C, and a final OD600 reading was measured. The change in OD600 was found by 
subtracting the initial OD600 from the final OD600 reading. A change in OD600 greater 
than 0.05 indicated positive growth. The minimum inhibitory concentration (MIC) was 
assigned as the lowest concentration of antibiotic or BPEI that inhibited bacterial growth. 
The fractional inhibitory concentration index (FICI) was calculated using the previously 




  (where A represents one drug and B 
represents the other). Synergistic effects are determined as by EUCAST guidelines: 
synergy (FICI ≤ 0.5), additivity (0.5 < FICI < 1), and indifference (FICI > 1).62 Each trial 
was done in triplicate. 
Growth Curves 
Tryptic Soy Broth (TSB) growth media augmented with various amounts of BPEI 
and/or oxacillin was inoculated at 0.5% from overnight cultures of MRSE 29887 and 
MRSE 35984. Cells were grown at 35°C with shaking. The OD600 was recorded every 
hour for each sample. Each study was done in triplicate. 
Scanning Electron Microscopy (SEM) 
MRSE 35984 and MSSE 12228 cells were inoculated 0.5%from an overnight 
culture and grown at 35C with shaking. Each strain of bacteria was grown in four separate 
conditions: BPEI, oxacillin, combination (BPEI+oxacillin), and control. The OD600 was 
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monitored, and growth was stopped at late-lag phase (OD600= 0.20–0.25). Samples were 
fixed with Karnovsky fixative (2% glutaraldehyde and 2% paraformaldehyde in 0.1M 
cacodylate buffer) for 30 min. The cells were then fixed with 1% OsO4 for 30 min in the 
dark. The cells were washed with water three times. A couple drops of each sample were 
placed on clean, poly-l-lysine coated coverslips and air-dried for 30 min. To dehydrate, 
the samples went through a series of ethanol solutions (20%, 35%, 50%, 70%, and 95%), 
spending 15 min in each solution. Afterward, the samples were dried with 
hexamethyldisilazane (HMDS) and sputter-coated with AuPd. A Zeiss NEON SEM was 
used to image the samples at 5kV accelerating voltage. Size analysis was performed on 
ImageJ. 
Transmission Electron Microscopy (TEM) 
MRSE 35984 cells were inoculated 0.5% from an overnight culture and grown at 
358Cwith shaking in four separate conditions: BPEI, oxacillin, combination 
(BPEI+oxacillin), and control. The OD600 was monitored, and growth was stopped at 
late-lag phase (OD600 = 0.20–0.25). Samples were fixed with Karnovsky fixative (2% 
glutaraldehyde and 2% paraformaldehyde in 0.1M cacodylate buffer) for 2 hr. The cells 
were washed three times with 0.2M cacodylate buffer and then stained with 1% OsO4 in 
1.5%potassium ferrocyanide for 2 hr in the dark. Samples were washed three times with 
water and stained with 1% uranyl acetate for 30 min. After three more washes with water, 
the cells were dehydrated with 50%, 70%, 95%, 95%, and 100% ethanol (20 min in each 
solution). The samples were immersed in propylene oxide (PO) for 1 hr to remove 
residual ethanol. The cell samples were then infiltrated with 2:1ofPO: Epon for 1h,1:1 of 
PO: Epon for 1hr, 2:1 of PO: Epon for 2hr, and pure Epon overnight. The cells were 
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transferred into embedding molds with fresh Epon and allowed to sink to the bottom for 
24–48 hat6 0 8C. The sample blocks were ultra-thin-sectioned by an ultramicrotome to 
80–100 nm thickness. The thin sections were placed on TEM copper grids and then 
stained with 1% uranyl acetate for 30 min. A JEOL2000FX TEM was used to image the 
samples at 200 kV accelerating voltage. Size analysis was performed on ImageJ. 
Results and Discussion 
Checkerboard assays indicate synergistic effects between BPEI and β-lactams 
To investigate the synergy between 600-Da BPEI and antibiotics against MRSE, 
checkerboard assays were conducted. Synergistic effects were observed between BPEI 
and b-lactam antibiotics (oxacillin, ampicillin, and amoxicillin), but not between BPEI 
and vancomycin (Table). Synergy occurred when their FICI was less than 0.5, while 
additivity was indicated by an FICI between 0.5 to 1.62 The MICs of BPEI and several 
antibiotics were tested against two laboratory strains of methicillin-resistant 
Staphylococcus epidermidis, MRSE ATCCS 29887 and MRSE ATCCS 35984, and one 
methicillin-susceptible strain, MSSE ATCCS 12228. As a result, the BPEI MICs for both 
MRSE 35984 (Figure 14A,B) and MRSE 29887 (Figure 14C–E) were 8 µg/mL, while 
the BPEI MIC for MSSE 12228 (Figure 14F) was 2 µg/mL. The oxacillin MICs for 
MRSE 35984, MRSE 29887, and MSSE 12228 were 32 µg/mL,8 µg/mL, and 0.1 µg/mL, 
respectively. Checkerboard assays showed synergy between BPEI and oxacillin against 
both MRSE 35984 (FICI= 0.5) and MRSE 29887 (FICI=0.375). In the presence of 4 
mgmL@1 600-Da BPEI, the oxacillin MICs for MRSE 35984 and MRSE 29887 were 
reduced from 32 to 4 µg/mL and from 8 to 0.5 µg/mL, respectively. Additionally, BPEI 
had synergy with amoxicillin (FICI=0.5) against MRSE 35984 and ampicillin 
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(FICI=0.31) against MRSE 29887. Linezolid was also found to have synergy or additivity 
with BPEI (FICI=0.38/0.75 against MRSE 35984/MRSE29887). No synergy was seen 
between BPEI and vancomycin (FICI=1, Figure 14E). BPEI did not potentiate β-lactam 
activity against the susceptible strain, MSSE 12228, which lacks PBP2a (FICI=1, Figure 
14F). The MIC of each antibiotic was lowered by a factor ranging from 4-fold (linezolid 
from 1 to 0.25 µg/mL) to 256-fold (amoxicillin from 64 to 0.25 µg/mL) when combined 
with 4 µg/mL BPEI (Table 3). To evaluate our approach further, two clinical MRSE 
isolates from patients at the University of Oklahoma College of Medicine were also 
tested. In Table , both clinical isolates had strong antibiotic resistance with high oxacillin 
MICs (64 and 128 µg/mL). When combined with 4 µg/mL BPEI, the MIC of oxacillin in 
both cases dramatically dropped to 2 µg/mL, making the bacteria no longer resistant. 
These data show that BPEI can effectively potentiate traditional antibiotics against 
MRSE. 
Table 3. Synergy of 600-Da BPEI and antibiotics against MRSE 
Strain Antibiotic MIC (µg/ml) MIC Antibiotic + 4µg/ml BPEI 
FICI Outcome 
BPEI Antibiotic   
MRSE 35984 
Oxacillin 8 32 4 0.5 Synergy 
Amoxicillin 8 64 0.25 0.5 Synergy 
Linezolid 8 1 0.25 0.38 Synergy 
Vancomycin 8 2 2 1 No synergy 
MRSE 29887 
Oxacillin 8 4 0.5 0.38 Synergy 
Ampicillin 8 32 0.5 0.31 Synergy 
Linezolid 8 1 0.25 0.75 Additivity 
Vancomycin 8 2 2 1 No synergy 
MRSE OU 26 Oxacillin 64 32 2 0.17 Synergy 





Figure 14. Checkerboard assays testing the synergy of BPEI and antibiotics on MRSE 
35984, MRSE 29887, and MSSE 12228. Synergy between BPEI and β-lactams was 
observed on MRSE 35984 (A, B) and MRSE 29887 (C, D), but not on MSSE 12228 
(F). No synergy was found between BPEI and vancomycin on MRSE 29887 (E). Each 
heat map is the average of three trials in the change of OD600. 
 
Synergistic effects were observed between BPEI and β-lactams but not 
vancomycin because the targets of b-lactams and vancomycin are distinctly different. 
Vancomycin binds to the D-Ala-D-Ala stems of bacterial cell wall peptidoglycan, 
whereas β-lactams bind to PBPs.63 BPEI binds to WTA, a cofactor of PBP2a, while WTA 
 
42 
is not connected with vancomycin activity. BPEI and β-lactams target the PBPs resulting 
in synergy: BPEI-WTA interaction inhibits PBP2a, while β-lactams inhibit the other 
PBPs. A similar explanation can be used to explain the data with methicillin-susceptible 
S. epidermidis (MSSE) that does not have PBP2a. Likewise, WTA is not involved in the 
regulation of other PBPs in MSSE. Therefore, disabling WTA does not potentiate 
antibiotics against MSSE. Wall teichoic acid (WTA) plays an important role in BPEI 
potentiation of β-lactams against the Gram-positive MRSE. Studies have shown that 
WTA is required for antibiotic resistance and biofilm formation in MRSE.64-67 By using 
NMR spectroscopy, Foxley et al. demonstrated that BPEI and WTA interacted via 
electrostatic binding of positively charged amine groups on BPEI and negatively charged 
phosphate groups on WTA.68 We believe a similar mechanism explains the results 
obtained in this study. Our hypothesis is that the BPEI-WTA attractions cause steric 
hindrance to prevent WTA-PBP2a interaction, thereby disabling the resistance factor 
PBP2a. The β-lactams prevent the other PBPs from cross-linking the cell wall; 
consequently, the MRSE cells are killed. Synergistic and additive effects of the BPEI+ 
antibiotic combinations signify enormous potential benefits for patient health because 
these first-line antibiotics are FDA-approved. Also, the low molecular weight 600-Da 
BPEI has been tested to have very low cytotoxicity and nephrotoxicity.45 Thus, BPEI 
could be a drug-candidate to treat MRSE infections. 
Growth curves confirm antimicrobial activity of oxacillin was restored  
Antimicrobial activity of oxacillin against MRSE 35984 and MRSE 29887 was 
restored by 600-Da BPEI. However, by comparing data in Figure 14, it is harder to disable 
resistance in MRSE 35984. This was confirmed by evaluating the time-dependence of 
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antimicrobial activity. Growth curves of the two resistant strains were monitored by 
recording their OD600 for 24 hours and are shown as the averages of three separate trials 
(Figure 15). The bacteria exposed to either BPEI alone or oxacillin alone reached 
stationary phase. However, each strain failed to do so in the combination treatment of 
BPEI+oxacillin. The OD600 increased for all of the samples except for those treated with 
the BPEI+oxacillin. In the BPEI+oxacillin treated samples, the OD600 dropped after 
4hours for MRSE 29887 and after 8hours for MRSE 35984. This indicates a strong 





Figure 15. BPEI restores bactericidal activity of oxacillin in the combination treatment 
(yellow curve) against both MRSE 29887 and MRSE 35984. Each growth curve is the 
average of three separate trials. Error bars denote standard deviation (n=3). 
 
Scanning and transmission electron microscopies confirm BPEI’s mechanism of action 
To better understand and confirm BPEI’s mechanism of action against MRSE, electron 
microscopy was used to examine treated samples of MRSE 35984 and MSSE 12228. 
Bacterial cells were collected at mid-log phase. SEM images of MRSE 35984 include the 
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untreated control, BPEI-treated, oxacillin treated, and combination BPEI+oxacillin-
treated samples (Figure 16). 
 
Figure 16. Scanning electron micrographs of MRSE 35984; scale bar = 1 µm. Untreated 
control cells appear smooth and rounded with clear division septa (arrows) (A). BPEI 
(256 µg/ml) treated cells (B) and oxacillin (2 µg/ml) treated cells (C) show no significant 
difference. Combination of BPEI+oxacillin (256 µg/ml + 2 µg/ml) treated cells (D) show 
extreme distortions and thicker division septa (inset). 
The cells in the control sample have smooth, rounded shapes with very clear 
division septa (Figure 16A). BPEI-treated (Figure 16B) and oxacillin-treated (Figure 
16C) cells show no noticeable differences in appearance. However, many of the cells 
exposed to the BPEI+ oxacillin combination have an abnormal appearance, including 
concave distortion and thicker division septa (Figure 16D). These cellular morphology 




Figure 17. Scanning electron micrographs of MSSE 12228; scale bar = 1 µm. Untreated 
control (A), BPEI (32 µg/ml) treated (B), oxacillin (0.003 µg/ml) treated (C), and 
combination of BPEI+oxacillin (32 µg/ml + 0.003 µg/ml) treated cells (D) show no 
noticeable differences. 
 
The majority of cells from BPEI-treated and the BPEI+ oxacillin treated samples 
(Figure 16B,D) appear qualitatively larger than the control sample. To confirm the 
difference in cell size, cell diameters were measured for both MSSE 12228 and MRSE 
35984. As shown in Figure 18A, MSSE 12228 did not show a statistically significant 
difference (ANOVA, p-value > 0.001) in cell size among the four treated groups: control 
(0.79 ± 0.06 µm), BPEI-treated (0.81± 0.09 µm), oxacillin-treated (0.79 ± 0.08 µm), and 
combination BPEI+oxacillin-treated (0.82 ± 0.07 µm). The cell sizes of MRSE 35984 
(Figure 18B) were found to be significantly different (ANOVA, p-value < 0.001) among 
the four treated groups: control (0.82 ± 0.07 µm), BPEI-treated (1.00 ± 0.10 µm), 
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oxacillin-treated (0.89 ±  0.07 µm), and combination BPEI+ oxacillin-treated (1.08 ± 0.15 
µm).  
 
Figure 18. Cell size measurements of MSSE 12228 and MRSE 35984 from SEM 
images among four treated groups: untreated control, BPEI (256 µg/ml) treated, 
oxacillin (2 µg/ml) treated, and combination BPEI + oxacillin treated. N=100 
cells/group. Mean value, X-marker; median value, center line; lower quartile and upper 
quartile, lower and upper ends of the box; minimum and maximum values, whiskers 
outside the box. No significant difference in cell size among treated groups in MSSE 
12228 (ANOVA, p-value > 0.001) (A). Significant difference in cell size among treated 
groups in MRSE 35984 (ANOVA, p-value < 0.001) (B). 
 
To further elucidate the mechanism of action for our BPEI+ β-lactam treatment 
against MRSE 35984, cross-sections of the four treated groups were imaged with TEM. 
TEM allows higher magnification and observation of intracellular structures of the cells. 
The untreated control cells (Figure 19A) have well-rounded morphologies and complete 
division septa, while BPEI-treated (Figure 19B) and oxacillin-treated (Figure 19C) 
samples display many incomplete division septa. The combination BPEI+ oxacillin-
treated cells (Figure 19D) have the largest sizes, abnormal multi-division septa, and 
unrounded shapes that the other treated groups do not possess. Each division septum 
appears thicker than in the other groups, supporting the SEM data (Figure 16D). Exposure 
to the BPEI+oxacillin combination makes MRSE cells unable to divide and ultimately 




Figure 19. Transmission electron micrographs of MRSE 35984; scale bar = 200nm; 
arrows show division septa. Untreated control cells appear rounded with complete 
division septa (A). BPEI (256µg/ml) treated cells (B) and oxacillin treated (2 µg/ml) cells 
(C) show incomplete division septa. Combination of BPEI + oxacillin (256 µg/ml + 2 
µg/ml) treated cells (D) appear to be the largest with abnormal division septa and concave 
morphology.  
 
The cell envelope of Gram-positive bacteria is a strong framework whose 
masonry-like architecture protects against internal turgor pressure and external attack by 
antimicrobial agents. The cell wall is maintained in a robust state by dynamic turnover 
that removes weakened portions while constructing new cell wall layers. Autolysins 
break down the cell wall by hydrolyzing the bond between N-acetyl muramic acid and 
N-acetylglucosamine groups of the peptidoglycan. Synthesis of new cell wall layers 
involves assembly of precursors in the cytoplasm prior to transport across the membrane. 
Next, transglycosylase and transpeptidase enzymes assemble the new components in their 
proper configuration. These processes establish the current strategy of interrupting cell 
wall construction as a target for many antibacterial drugs. β-lactam antibiotics bind to 
transpeptidase penicillin binding proteins (PBPs) to prevent cross-linking of nascent 
peptidoglycan. Degradation by autolysins coupled with the inability to replace 
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peptidoglycan leads to thinning of the cell wall, loss of integrity, and rupture from internal 
pressure. However, MRSE endures by expressing PBP2a, whose enzymatic functions 
proceed in the presence of b-lactams. Cationic BPEI binds to anionic WTA to prevent 
WTA function, one of which is to serve as a scaffold for PBP2a enzymatic activity. In 
this manner, BPEI disables resistance from PBP2a. 
Conclusions 
Antimicrobial resistance is a critical and increasing world-wide threat to the 
public health. The CDC estimates that at least 2 million people in the U.S. alone are 
infected by antibiotic-resistant bacteria annually, leading to 23,000 deaths and $20 
billion/year in US healthcare costs.69 The threat from MRSE appears lower than MRSA 
because of reduced virulence and fewer toxins. However, with its ubiquitous niche on the 
human skin, MRSE cannot be overlooked. S. epidermidis bacteria can be found on nearly 
every medical device.70 Fortunately, WTA in these bacteria is a weakness in antimicrobial 
resistance mechanisms.71-73 Previous attempts to disable PBP2a by stopping WTA 
biosynthesis have not survived preclinical trials. Both MRSA and MRSE employ PBP2a, 
whose functionality requires the presence of WTA. Their resistance can be overcome by 
disabling WTA, as demonstrated with WTA-deficient strains of MRSA (ΔtarO 
mutants),71 by inhibiting the WTA synthesis protein TarO with tunicamycin,74 or by 
inhibiting another biosynthesis protein, TarG, with Targocil®.72, 75-77 The work in these 
reports is strong. Targocil® and related compounds suffer from protein binding that 
reduces in vivo efficacy,78 but new compounds have mitigated this drawback.79 
Compounds that inhibit WTA and potentiate β-lactams against MRSA also lead to 
potentiation against MRSE.72  
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Nevertheless, WTA remains an under exploited weakness, and our data show that 
cationic 600-Da BPEI targets this weakness.80-81 We depart from the status quo of 
stopping WTA biosynthesis72, 74 and instead target mature WTA. WTA is an anionic 
phosphodiester, and cationic 600-Da BPEI disables WTA via an electrostatic interaction. 
This, in turn, disables PBP2a. In combination, 600-Da BPEI and β-lactam antibiotics 
inhibit MRSE growth (this work) and MRSA growth.80-81 The effect is characterized as 
synergistic from the FICI. Measuring MRSE growth reveals that bacteria exposed to sub-
lethal concentrations of BPEI and oxacillin fail to reach exponential phase when the two 
compounds are combined. This data indicates that the mechanism by which BPEI + 
oxacillin prevents growth of MRSE is bactericidal. Additional checkerboard assays 
demonstrate anti-MRSE potency of amoxicillin and ampicillin mixed with 600-Da BPEI. 
Likewise, higher 600-Da BPEI concentrations decrease further the antibiotic MIC values. 
Yet, potentiation of linezolid challenges the premise that our discovery applies to WTA-
based resistance mechanisms, such as the function of PBP2a. From calculation of the 
FICI, the effect is a characterized as additive rather than synergy, and thus BPEI and 
linezolid affect different bacterial components. We know that BPEI binds to anionic sites 
of the cell wall envelope80-81 whereas linezolid acts in the cytoplasm to interfere with 
protein synthesis via the ribosomal 50S subunit. The potentiation of linezolid is most 
likely to occur by increasing its permeation into the cytoplasm. Therefore, BPEI reduces 
barriers from the cell membrane and/or the extracellular slime of MRSE. Yet, 600-Da 
BPEI does not alter the MIC of vancomycin, whose mode-of-action is constrained to the 
cell wall peptidoglycan. Work to evaluate increased cross-membrane permeation of 
antibiotics due to the presence of 600-Da BPEI is underway. 
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The overuse of antibiotics is reflected in the pervasiveness of MRSE. From 
previous studies, the staphylococcal cassette chromosome mec, which codes for 
methicillin resistance, is suggested to be a one-way horizontal gene transfer from S. 
epidermidis to the well-known super-bug, MRSA.82-84 As a ubiquitous commensal 
species of human microflora, S. epidermidis contains an optimum reservoir for antibiotic 
resistance genes, making it an implicit danger. Catheter-related bloodstream infections 
(CRBSI) are caused primarily by coagulase-negative Staphylococci, which include S. 
epidermidis, and they can usually be treated with glycopeptides (such as vancomycin) 
without catheter removal. However, the chances of bacteremia recurring could be as high 
as 20%,85 and the effectiveness of the last-resort antibiotics (linezolid, vancomycin, and 
daptomycin) has been reduced significantly against MRSE.86-87 Some MRSE clinical 
isolates have intermediate resistance to vancomycin and caused complications in patients 
with sepsis and peritonitis.88-89 Thus, a need exists to evaluate methods of combating these 
infections. Our strategy of combining traditional β-lactams with BPEI holds promise in 
the ongoing battle against MRSE.   
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Chapter 4: BPEI potentiates β-lactam antibiotics against  
MRSE biofilms 
Background 
Staphylococcus epidermidis belongs to the Gram-positive Staphylococcus genus. 
It has emerged as one of the most common causes of healthcare-associated infections 
due to the increasing use of medical implant devices.17, 90 Unlike the coagulase-positive 
Staphylococcus aureus, S. epidermidis does not produce coagulase and therefore is 
classified under coagulase-negative staphylococci (CoNS). Accounting for about 70% 
of all CoNS on human skin, S. epidermidis is a leading cause of severe bloodstream 
infections. Approximately 80,000 cases of central venous catheter infections per year in 
the US are caused by S. epidermidis.91  S. epidermidis is an opportunistic pathogen, like 
most of the CoNS, because they lack aggressive virulence factors (like those in S. 
aureus) and instead owe their pathogenic success to the ability to form biofilms. 
Biofilms and Multidrug Resistance 
Biofilms are multicellular agglomerations of microorganisms enclosed in a 
matrix of extracellular polymeric substances (EPS). Containing polysaccharides, 
proteins, and extracellular DNA, the EPS matrix acts as a shield that protects the 
organisms from host defenses and antibiotics. Biofilms can adhere to either biotic or 
abiotic surfaces—such as cardiac pacemakers and catheters—and have a highly 
regulated defense mechanism that grants intrinsic resistance against antimicrobial 
agents.92 Biofilm development starts with an initial attachment of planktonic cells to a 
surface, which then grow into clusters of multicellular colonies. Subsequent cell-cell 
adhesions, divisions, and secretion of EPS create a three-dimensional architecture 
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designed to channel water and supply nutrients to the inner layers, thereby allowing for 
biofilm maturation. While the outer-layer cells remain metabolically active, the inner-
layer cells are persister bacteria that often stay in a dormant state, and thus are the most 
difficult to eradicate with antimicrobial treatments, that only target growing 
organisms.93  During biofilm maturation, part of the biofilm can detach and disperse 
planktonic cells, which spread to colonize new surfaces. Mechanisms of biofilm 
maturation and detachment are poorly understood, but studies suggest that dispersed 
cells are more virulent and heighten the risk of acute infections.18, 93  
Biofilm defense mechanisms reduce antibiotic efficacy. The antibiotic 
concentrations required to eradicate biofilms are ten- to a thousand-fold higher than the 
concentrations required to kill planktonic bacteria, creating a burden on both public 
health and the economy from increased medical costs. Removal of biofilm-infected 
indwelling medical devices complicates treatments and interferes with the healing 
process.92  Additionally, persistent biofilms are also a leading cause of chronic wound 
infections. Around 60% of chronic wound specimens—compared to only 6% for acute 
wounds—were found to contain biofilms in which the prevalent species was 
Staphylococci.94  Thus, few publications offer information on S. epidermidis biofilm 
properties and antibiofilm testing, and the virulence and resistance factors of S. 
epidermidis biofilms are poorly understood.93  Nevertheless, it is necessary to 




Figure 20. Biofilm formation stages and biofilm-disrupting ability of BPEI. BPEI 
disrupts established biofilm by collapsing the structure of EPS, releasing the cells into 
planktonic stage so that β-lactam antibiotics can actively target and eradicate them. 
Bacterial biofilms that are impenetrable to antibiotics pose an even greater threat 
when they are created by drug resistant bacteria, such as methicillin-resistant S. 
epidermidis (MRSE). MRSA, MRSE, and their biofilms lead to chronic wound 
infections (i.e. wounds that have not proceeded through a reparative process in three 
months) that affect millions of Americans each year.55-56, 58  With a dwindling arsenal of 
new antibiotics, existing drugs and regimens must be coupled with potentiators and re-
evaluated as combination treatments for biofilms and antibiotic-resistant diseases. Our 
lab previously examined the efficacy of branched polyethylenimine (BPEI), a cationic 
polymer with a low molecular weight of 600-Da, against planktonic MRSE bacteria. 
Cationic BPEI, with many primary and secondary amine groups, indirectly targets the 
resistant factor PBP2a by electrostatically binding to anionic wall teichoic acid required 
for PBP2a activity. In this manner, BPEI disabled resistance in MRSE strains, restoring 
their susceptibility to traditional β-lactam antibiotics.1  In this chapter, we further 
investigate the application of our technology to MRSE biofilms where the EPS contains 
numerous anionic biomacromolecules. The EPS creates a hydrophobic barrier that 
increases the tolerance of bacteria towards antimicrobials by reducing or preventing the 
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antibiotics from reaching their target(s). When BPEI binds to EPS, two changes will 
occur. First, the anionic character of the biofilm will be neutralized leading to a 
disruption of the EPS matrix. Secondly, because BPEI is a hydrophilic polymer, it will 
disrupt hydrophobic barriers that hinder diffusion of aqueous antibiotics (Figure 20). 
Thus, BPEI functions as a potentiator by inhibiting and disrupting the EPS matrix 
allowing antibiotics to enter and kill the bacteria. Using the MBEC (Minimum Biofilm 
Eradication Concentration) assay, which is represented in Figure 21 as a schematic 
flow, our study demonstrates that BPEI possesses antibiofilm activity itself at high 
concentrations. However, we also observe synergy between lower concentrations of 
BPEI and β-lactams against MRSE biofilms. Because it can both disable resistance 
mechanisms and eradicate biofilms, BPEI is a dual-function potentiator, making it a 





Figure 21. A schematic experimental procedure of our microtiter biofilm model for 
synergistic effect screening against methicillin-resistant S. epidermidis (MRSE) 
biofilms. MBEC assays were carried out using MBEC inoculator, which is a microtiter 
plate lid with protruding prongs attached. Each prong fits into each well and allows 
bacterial biofilm to form and grow. Details are given in the Experimental Procedures. 
The method of CFU counting is detailed in Biofilm Kill Curve. 
Purpose of Experiment 
The purpose of this experiment is to determine the antibiofilm synergy of BPEI 
and β-lactams against multidrug-resistant Staphylococcus epidermidis. 
Experimental Procedures 
Materials 
In this experiment, the Staphylococcus epidermidis bacteria were purchased 
from the American Type Culture Collection (ATCC 29887: methicillin-
resistant/biofilm-producer, ATCC 35984: methicillin-resistant/biofilm-producer, and 
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ATCC 12228: methicillin-susceptible/non-biofilm producer). Chemicals were 
purchased from Sigma-Aldrich (DMSO, growth media, and electron microscopy 
fixatives). Antibiotics were purchased from Gold Biotechnology. 600-Da BPEI was 
purchased from Polysciences, Inc. MBEC™ Biofilm Inoculator with 96-well base 
plates were purchased from Innovotech, Inc.  
MBEC Assay 
(The MBEC assay is adapted from previous literature reports.95-97) 
Inoculation and Biofilm Formation: A sub-culture of MRSE was grown from the 
cryogenic stock on an agar plate overnight at 35 °C. The MBEC plate was inoculated 
with 150 µL of TSB/well plus 1 µL of a stock culture made from 1 colony/mL of 
MRSE in TSB. The MBEC inoculator plate was sealed with Parafilm and incubated for 
24 hours at 35 °C with 100 rpm shaking to facilitate biofilm formation on the prongs. 
Following biofilm formation, the lid of the MBEC inoculator was removed and placed 
in a rinse plate containing 200 µL of sterile PBS for 10 sec. Biofilm growth check 
(BGC) was performed by breaking a few prongs off using sterile pliers, submerging 
them in 1 mL PBS, and sonicating them on high for 30 minutes to dislodge the biofilm. 
After sonication, the biofilm solution was serial-diluted and spot-plated on agar plates 
for CFU counting to determine the biofilm density on the prongs. 
Antimicrobial Challenge: A challenge plate was made in a new pre-sterilized 
96-well plate in a checkerboard-assay pattern (followed the methods of Lam et al.1) to 
test the synergistic activity of BPEI + antibiotic combinations. Antimicrobial solutions 
were serial-diluted and added to the 96-well plate, which contained 200 µL of cation-
adjusted Mueller-Hinton broth (MHB) per well. Following the rinsing step and biofilm 
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growth check, the MBEC inoculator lid was immediately transferred into the prepared 
antimicrobial challenge plate and incubated at 35 °C for 20-24 hours.  
Recovery and Quantitative MBEC: After the challenge period, the MBEC 
inoculator lid was transferred into a recovery plate containing 200 µL of MHB per well, 
sonicated on high (Branson B-220, frequency of 40 kHz) for 30 minutes to dislodge the 
biofilm and then incubated at 35 °C for 20-24 hours to allow the surviving bacterial 
cells to grow. After incubation, the OD600 (optical density at 600 nm) of the recovery 
plate was measured using a Tecan Infinite M20 plate reader to determine the MBEC of 
the antimicrobial compounds tested. A change in OD600 greater than 0.05 indicated 
positive growth. Likewise, the OD600 for the base of the challenge plate was measured 
immediately after inoculation to determine the MICs of the antimicrobial compounds. 
The fractional inhibitory concentration index (FICI) calculated based on established 
equation98 was used to determine synergy (FICI < 0.5), additivity (0.5 < FICI < 1), and 
no synergy (FICI = 1).  
Scanning Electron Microscopy 
MRSE 35984 cells were inoculated from 0.5 % of an overnight culture and 
grown at 35 °C with shaking in the MBEC biofilm inoculator for 24 hours to facilitate 
biofilm formation on the prongs. Prongs were broken off the plate using a sterile plier, 
submerged, treated with primary fixative (5 % glutaraldehyde in 0.1 M cacodylate 
buffer) in a capped vial, and incubated at 4 ± 2 °C for 2 days. The prongs were removed 
from the fixing solution and air-dried for 72 hours in a fume hood. They were mounted 
on aluminum stubs with carbon tape and sputter-coated with AuPd. A Zeiss NEON 
SEM was used to image the samples at 5 kV accelerating voltage.  
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In a different experiment, MRSE 35984 cells were inoculated from 0.5 % of an 
overnight culture and grown at 35 °C with shaking in the MBEC biofilm inoculator for 
3 days to ensure maturation of biofilms on the prongs. Nutrient media was replaced 
every 24 hours. After 3 days, biofilms on the prongs were submerged into new 96-well 
base with BPEI (512 µg/mL) for 24 hours of treatment. Then, the prongs were broken 
off the plate using a sterile plier, submerged, fixed with primary fixative (5 % 
glutaraldehyde in 0.1 M cacodylate buffer) in a capped vial, and incubated at 4 ± 2 °C 
for 2 days. The prongs were removed from the fixing solution and air-dried for 72 hours 
in a fume hood. They were mounted on aluminum stubs with carbon tape and sputter-
coated with AuPd. A Zeiss NEON SEM was used to image the samples at 5 kV 
accelerating voltage.  
Biofilm Disrupting Assay 
Two similar sets of the experiment were conducted: one used 600-Da BPEI and 
the other used 10,000-Da BPEI. A sub-culture of MRSE 35984 was grown from the 
cryogenic stock on an agar plate overnight at 35 °C. A pre-sterilized 96-well tissue-
culture treated plate was inoculated with 100 µL of TSB/well plus 1 µL of a stock 
culture made from 1 colony/mL of MRSE in TSB. The plate was incubated at 35 °C for 
24 hours to form established biofilm.99-100 Planktonic bacteria were removed by 
washing 5 times with water. Crystal violet solution (0.1%) was used to stain the biofilm 
by adding 100 µL of the solution to each well for 15 minutes. The plate was then 
washed 5 times with water to remove all excess cells and dye. The plate was turned 
upside down and air-dried overnight. 
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Six separate treatments were performed on the preformed biofilm plate (total 
volume of 100 µL/well): untreated (negative control), BPEI-treated (32, 64, 128, and 
256 µg/mL), and 30 % acetic acid-treated (positive control). The treated samples were 
incubated at room temperature overnight to test the biofilm-disrupting ability of BPEI. 
Carefully, without touching the bottom of the plate, the solubilized solution in each well 
was transferred to a new flat-bottom plate for an absorbance measurement of OD550. The 
OD550 represents the amount of MRSE biofilm that was disrupted by BPEI, allowing for 
quantitative comparison of the controls and treated samples. Statistical data analysis 
among treated samples was performed using t-test, n = 10.  
Minimum Biofilm Inhibitory Concentration (MBIC) 
MBIC assays were conducted in a similar fashion as checkerboard assays. The 
full procedure for checkerboard assays are outlined in Lam et al.1 In brief, a 
checkerboard assay was made in a 96-well plate to examine the synergy between BPEI 
and an antibiotic. After an overnight incubation, the cell suspension in the plate was 
discarded and washed with 100% methanol to retain only the biofilm attached on the 
well surface. Next, crystal violet solution (0.1%) was used to stain the bacterial biofilm 
for 15 minutes then washed three times with water. Stained biofilm was then dissolved 
with 95% ethanol for an OD550 (optical density at 550 nm) measurement. Data were 
subtracted from positive control values and reported. 
Biofilm Kill Curve 
Biofilm was grown in an MBEC inoculator plate for 24 hours with shaking to 
facilitate biofilm formation. At time zero, the prongs were sonicated in PBS for 30 
minutes and then plated on agar for CFU counting. Four separate treatments were 
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performed in a new 96-well base: Group 1 was the untreated control, Group 2 had 64 
µg/mL of BPEI, Group 3 had 16 µg/mL of oxacillin, and Group 4 had a combination of 
64 µg/mL of BPEI + 16 µg/mL of oxacillin. The prongs on the MBEC inoculator were 
washed in PBS for 10 seconds and then transferred into the new treated base plate and 
incubated. Agar CFU plating was performed at 2 hours, 4 hours, 8 hours, and 24 hours 
for each treatment group. All the agar plating was incubated at 35 °C and counted for 
colony forming units the next day. Each trial was done in duplicate.  
Results and Discussion 
During the staphylococcal biofilm attachment stage, bacteria adhere to a surface 
through non-covalent interactions (e.g. electrostatic bonds) via microbial surface 
components recognizing adhesive matrix molecules. The next stages are biofilm 
proliferation and maturation, during which EPS (containing proteins, polysaccharide 
intercellular adhesin PIA/PNAG, teichoic acids, and eDNA) and channel architecture 
are produced. During the last stage—biofilm detachment and dispersal—phenol soluble 
modulin peptides disrupt the non-covalent interactions established in the attachment 
stage.101  To survive in the human body, pathogens need to cope with the host defense 
mechanisms: the innate immune system, which includes neutrophils and antimicrobial 
peptides (AMPs) and the acquired immune system, which includes antigen-dependent T 
and B cells. The latter is ineffective against MRSE infections for reasons that are not 
well understood.102  Since they have been colonizing human skin for millennia, perhaps 
S. epidermidis strains have evolved ways to evade the host defenses. These recalcitrant 
biofilms particularly threaten immunocompromised patients and those who need 
prosthetic limbs or artificial implant devices because biofilms can survive on abiotic 
 
62 
surfaces for weeks to months.18  Motivated to join in the fight against MRSE biofilm 
infections, we are testing our combination treatment of BPEI and β-lactams in an 
MBEC microtiter biofilm model. 
Confirmation of MRSE Biofilms 
The MBEC plates with protruding-prong lids (shown in Figure 21) were used in 
our experiments to determine the antibiofilm activity of BPEI and conventional 
antibiotics. The prong lids with established biofilms can fit into regular 96-well 
microtiter plates for further antimicrobial assays. Many biofilm studies fail to confirm 
biofilm presence before applying treatments. In this study, scanning electron 
microscopy (SEM) was performed to confirm that MRSE biofilms formed on the 
prongs after 24 hours inoculation. Compared to the smooth surface of the control prong 
(Figure 22A), numerous microcolonies of MRSE were found on the inoculated prong 
(Figure 22B), indicating that these prongs provide surfaces for biofilm attachment and 
development. To better characterize the MRSE biofilm morphology, higher 
magnifications were obtained. Images depict spherical cocci of MRSE bacteria enfolded 
in a “blanket-like” coat of EPS matrix (Figure 23A). The layers of bacteria are 
intertwined throughout the matrix, confirming the three-dimensional architecture and 
the existence of EPS in biofilms (Figure 23B).Among many substances in the EPS 
matrix, the poly-N-acetylglucosamine (PNAG, also known as PIA) polymer in 
particular was suggested to have a critical impact on S. epidermidis biofilms both in 
vitro103-104 and in vivo.33, 35, 105  Generated from the ica locus, this homopolymer is 
believed to interact with surface proteins and protect against host defense mechanisms 
during biofilm formation. Another important protective exopolymer is the 
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pseudopeptide polymer poly-γ-DL-glutamic acid (PGA), which is encoded by the cap 
gene. Although PGA is produced in very small amounts, it plays a pivotal role in S. 
epidermidis resistance against host AMPs and leukocyte phagocytosis.106  These 
biopolymers, along with teichoic acids and eDNA, comprise the slime-like EPS coat. 
The SEM images confirm that established MRSE biofilms have formed before 
treatment with BPEI and β-lactam combinations. 
 
Figure 22. Scanning Electron Micrographs of the tip of MBEC prongs. A control prong 
with no bacteria is shown (A). MRSE 35984 biofilm colonies were formed after 24 
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hours of inoculation (B); the arrows highlight some of the biofilm microcolonies. Scale 
bars = 200 µm. 
 
Figure 23. Scanning electron micrographs of MRSE 35984 biofilm. The intercellular 
matrices of EPS are captured as they wrap around every bacterium (A). At higher 
magnification, the EPS matrix is clearly shown to be sheltering the whole bacterial 
colony in an amorphous coat (B). Scale bars = 2 µm. 
Efficacy of BPEI and β-lactams Against MRSE Biofilms 
In our previous study, disabling PBP2a with 600-Da BPEI re-sensitizes MRSE 
to β-lactams.1  Here, we investigated a combination of BPEI and β-lactam antibiotics 
(oxacillin and piperacillin) against biofilms formed by two MRSE strains, MRSE 
ATCC 35984™ and MRSE ATCC 29887™. The MICs of BPEI and the antibiotics 
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were found using the antimicrobial challenge plates, which measured the change in 
OD600 of planktonic bacteria. The results are consistent with our previously published 
study.1  Sonication of the prongs into a recovery plate allows us to measure the MBEC 
values, which were found to be much higher than the corresponding MIC values. This 
illustrates the intrinsic resistance of biofilms. For MRSE 35984, the oxacillin MIC is 16 
µg/mL, while the oxacillin MBEC is 512 µg/mL (Figure 24Aa). Likewise, for BPEI, the 
MIC is 8 µg/mL whereas the MBEC is 256 µg/mL (Figure 24Ab). Synergy occurs when 
an FICI is less than 0.5.98 With the addition of 8 µg/mL of BPEI, a synergistic effect 
lowered the MBEC of oxacillin from 512 to 32 µg/mL (FICI = 0.19). Higher amounts 
of BPEI lowered oxacillin MBEC values further—for instance, 32 µg/mL of BPEI leads 
to an 8 µg/mL MBEC value for oxacillin (FICI = 0.28). For MRSE 29887, the 
piperacillin MIC is 512 µg/mL, and the BPEI MIC is 64 µg/mL (Figure 24Ba). 
Although the MBEC values for this strain were found to exceed 512 µg/mL (Figure 
24Bb), synergy between 64 µg/mL piperacillin and 128 µg/mL BPEI (FICI = 0.19) 




Figure 24. Synergistic effects of BPEI and antibiotics against MRSE 35984 (A) and 
MRSE 29887 (B) on a 96-well checkerboard pattern. The synergy was seen both on the 
planktonic challenge plates (A,a and B,a) and the biofilm MBEC assays (A,b and B,b). 
BPEI Possesses Biofilm-Disrupting Potential 
Antibiofilm activity of BPEI was supported by the biofilm disrupting assay 
(Figure 25). Established biofilms of MRSE 35984 were stained with crystal violet and 
then treated with 32, 64, 128, and 256 µg/mL of 600-Da BPEI. A negative control (0 
µg/mL BPEI) and a positive control (acetic acid) were also performed. After 20 hours 
of treatment, BPEI-treated data was compared with the negative control using Student’s 
t-test, and the results indicated that the MRSE biofilms were significantly dissolved by 
600-Da BPEI (n = 10, p-value < 0.01). The dissolved biofilm solutions were carefully 
transferred to a new plate (without touching the bottom of the wells) for OD550 
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measurement. As shown in Figure 25A, MRSE biofilm remained intact in the bottom of 
the negative control well, while the biofilm in the 32 and 64 µg/mL BPEI-treated wells 
were partially dissolved into solution. Biofilms treated with 128 and 256 µg/mL BPEI 
were completely dissolved, as was the biofilm treated with the positive control of acetic 
acid. Figure 25B shows the OD550 values of the crystal violet absorbance, which 
represent the amount of biofilm dissolved in each treatment.  
 
Figure 25. Established MRSE 35984 biofilms stained with crystal violet were treated 
with 600-Da BPEI for 20 hours, as well as the negative and positive controls. The 
dissolved biofilm solutions were transferred to a new plate, and the biofilm remainders 
are shown as top-down view, (A). The mean OD550 of the dissolved biofilms was 
measured, (B). Error bars denote standard deviation (n = 10). The MRSE biofilms were 
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significantly dissolved by 600-Da BPEI (t-Test, p-value < 0.01, significant difference 
between the negative control and each treatment is indicated with an asterisk). 
A similar experiment was conducted using 10,000-Da BPEI (Figure 26). As 
with 600-Da BPEI, the t-test indicated that 10,000-Da BPEI dissolved MRSE biofilms 
(n = 10, p-value < 0.01). Greater biofilm disruption effects were seen at 64 µg/mL of 
10,000-Da BPEI-treated samples (OD550 = 2.60, Figure 26B) than at 64 µg/mL of 600-
Da BPEI treated samples (OD550 = 1.59, Figure 25B). According to Wiegand et al., even 
though high molecular weight BPEIs (over 25 000 Da) are toxic, 600 Da BPEI has high 
biocompatibility and a low likelihood for mutagenesis.107 We have been able to confirm 
these observations using in vitro nephrotoxicity assay. Furthermore, 600 Da BPEI is not 
toxic toward colon, kidney, and HeLa cells unless the concentration is orders-of-
magnitude higher than the amount required for potentiation.45, 68 These factors suggest 
that a combination treatment for biofilms of bacteria with or without antibiotic 
resistance could be accomplished with antibiotics given topically, orally, or 
intravenously while BPEI potentiators are administered topically. Using BPEI in this 
manner would disable biofilms and resistance mechanisms while lowering concerns of 
BPEI toxicity. Additional work is required to measure the transdermal flux and 
determine if toxic levels of 600 Da BPEI can reach the dermal and subcutaneous skin 




Figure 26. Established MRSE 35984 biofilms stained with crystal violet were treated 
with 10,000-Da BPEI for 20 hours, as well as the negative and positive controls. The 
dissolved biofilm solutions were transferred to a new plate, and the biofilm remainders 
are shown as top-down view, (A). The mean OD550 of the dissolved biofilms was 
measured, (B). Error bars denote standard deviation (n = 10). The MRSE biofilms were 
significantly dissolved by 10,000-Da BPEI (t-Test, p-value < 0.01, significant difference 
between the negative control and each treatment is indicated with an asterisk). 
Biofilm Inhibition and Eradication Using Combination of BPEI + β-Lactams 
Crystal violet assays were used to demonstrate that BPEI synergizes with 
piperacillin to inhibit MRSE biofilm formation. This assay is similar to the 
checkerboard assay used in our previous study.1  However, we tested the antibiofilm 
activity instead of the MICs, so a modified procedure was used. Twenty-four hours after 
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inoculation in a 96-well checkerboard plate containing combinations of 600-Da BPEI 
and piperacillin, the cell suspension supernatant was discarded, leaving the attached 
biofilms, which were then stained with crystal violet for measurement at OD550 to 
quantify the remaining biomass. The Minimum Biofilm Inhibitory Concentration 
(MBIC) of BPEI was found to be 64 µg/mL, and the MBIC of piperacillin was 64 
µg/mL. As shown in Figure 27, less biofilm formed in BPEI + piperacillin combination 
wells than in the piperacillin wells. Additionally, higher concentrations of BPEI 
corresponded to greater inhibition of biofilm formation. For example, 8 µg/mL of BPEI 
and 16 µg/mL of piperacillin prevented biofilm growth, however 16 µg/mL of BPEI 
also prevented biofilm growth when combined with 8 µg/mL of piperacillin. These 
results confirm that 600-Da BPEI possesses inhibitory activity against MRSE biofilms. 
 
Figure 27. Crystal violet absorbance represents MRSE 35984 biofilm biomass. Strong 
antibiofilm formation synergy between BPEI and piperacillin was observed, compared 
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to individual piperacillin or BPEI treated samples. Error bars denote standard deviation 
(n = 3). PIP, piperacillin. 
No antibiotic currently on the market can eradicate pathogenic biofilms, but the 
combination treatment of BPEI + oxacillin showed promise. Established biofilms of 
MRSE 35984 were treated in four different groups: Untreated control, BPEI-treated, 
oxacillin-treated, and combination (BPEI + oxacillin)-treated. A kill curve was 
generated to compare the antibiofilm activities of the treatments (Figure 28). Before 
treatment, all four groups had the same cell density of approximately 105 CFU/mL of 
bacteria. After treatments, the cell densities of each treated group were monitored by 
serial-diluting and agar-plating the sonicated prongs. Neither BPEI-treated nor 
oxacillin-treated groups could eradicate the biofilms, though they did inhibit the rate of 
the bacterial growth compared to the untreated control. At time 24 hours, cell densities 
were ~107 CFU/mL in the control group, ~105 CFU/mL in the BPEI-treated group, and 
~103 CFU/mL in the oxacillin-treated groups. Since implantable medical devices have 
ample surface area for bacterial colonization, even a low bacterial inoculum (~102 
CFU/mL S. aureus108 ) can provoke an infection. Oxacillin did eradicate some 
biofilm—as indicated by its declining kill curve in Figure 28—but the remaining 
persister bacteria within the biofilm on the treated prongs (>103 CFU/mL at 24 hours) 
are sufficient to grow and spread to new niches. Compared to the control group at time 
24 hours (~107 CFU/mL), the combination treatment of BPEI + oxacillin reduced the 
cell density of the biofilms by 100,000-fold (<101 CFU/mL), illustrating the 




Figure 28.  Biofilm kill curve of MRSE 35984. Only the combination treatment of 
BPEI+oxacillin (64 µg/mL + 16 µg/mL) – the diamond-curve – could eradicate MRSE 
35984 biofilms. Error bars denote standard deviation (n = 2). CFU, colonies forming 
units. 
Efficacy of BPEI on 3-Day-Old Biofilms 
To test our technology against a more realistic chronic wound model, we 
qualitatively investigated BPEI’s effects on a 3-day-old MRSE biofilm. MRSE 35984 
was grown on the MBEC device for 3 days prior to treatment. Then, the untreated 
control and the BPEI-treated (512 µg/mL) samples were fixed and imaged for 
microscopic analysis. As shown in Figure 29, the untreated MRSE biofilms were thick, 
and encased in EPS (Figure 29A), and they densely occupied the entire prong surface 
(Figure 29C). In contrast, after BPEI treatment, the EPS coat was visibly disrupted 
which reveal the bacterial cells with a thin or non-existent EPS coating (Figure 29B), 
and a greater proportion of the prong surface was exposed (Figure 29D). These results 
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indicate that BPEI not only can effectively potentiate antibiotics against planktonic 
cells, but also against the established biofilms through an EPS-disruption mechanism. 
The exposure of the individual cells without the EPS protection would make them more 
vulnerable to antimicrobial agents, increasing the likelihood of clinical treatment 
success against persistent pathogenic biofilms. 
 
Figure 29. Scanning electron micrographs of established MRSE 35984 biofilms (3-day 
old). The untreated control sample shows thick EPS enfolding every bacterial cell (A). 
BPEI-treated sample shows disrupted EPS and significant number of exposed cells 
without the EPS (B). At lower magnification, the untreated control (C) biofilms appear 
with full and tightly occupied biofilms, while the BPEI-treated sample (D) shows 
disjointed biofilms by many revealed surfaces. Scale bars (A and B) = 1 µm. Scale bars 
(C and D) = 100 µm. 
Many studies have tested cationic agents against pathogenic biofilms.  In one 
study, Bottcher et al. used norspermidine, a natural trigger for Bacillus subtilis biofilm 
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disassembly, to synthesize mimetic cationic compounds. Their compounds were able to 
disrupt established biofilms of B. subtilis and S. aureus. A library of synthetic guanidine 
and biguanidine polyamines were shown to inhibit biofilm formation although few were 
able to disrupt established biofilms.109  Our approach to biofilm treatment is unique 
because BPEI, a small macromolecule, can be a biofilm inhibitor and disruptor against 
not only the susceptible strains but also the resistant staphylococcal strains with the 
added benefit of disabling antimicrobial resistance mechanisms of planktonic cells. As a 
dual-function potentiator, 600-Da BPEI is a more powerful and versatile therapeutic 
agent than other cationic polymers. 
Conclusions 
According to the Centers for Disease Control and Prevention, most human 
bacterial infections involve biofilm-producing pathogens from common diseases (such 
as periodontitis, chronic prostatitis, and cystic fibrosis), which can infect artificial 
protheses.110  Staphylococcus epidermidis is the most prevalent microorganism isolated 
from CoNS infections of chronic wounds, medical device-related infections, and 
postoperative endophthalmitis.91, 111  Eradicating established microbial biofilms remains 
a difficult endeavor in both research and clinical settings. EPS frustrates the therapeutic 
efficacy of almost every available antibiotic. High dosages of antibiotics can be toxic to 
the human body and often cause adverse side effects. Therefore, drug developers need 
to stock the arsenal with alternative approaches that eliminate biofilm infections without 
harming the body’s natural defenses. Bacteria within a biofilm differ from their 
planktonic counterparts in a number of ways, including using the matrix of EPS, 
extracellular DNA, and extracellular WTA as barriers against antimicrobial agents.31, 65-
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67, 112-118  By targeting WTA-mediated resistance in MRSA/MRSE, 600-Da BPEI acts as 
a dual-function potentiator that can improve wound care outcomes by restoring potency 
to existing antibiotics. Overall, the strong synergy between BPEI and β-lactam 
antibiotics make this combination a promising treatment for S. epidermidis biofilms 
because 600-Da BPEI’s in vitro cytotoxicity is low,45, 68  and lower antibiotic 
concentrations reduce adverse side effects. Future experiments will be conducted to 
elucidate the antibiofilm mechanism of our combination therapy and to test our 
technology against more virulent superbugs. With the evolution of microorganisms 
outpacing our development of new drugs, it is imperative that different strategies are 
developed and implemented quickly. Hopefully, our approach will mark a turning point 
in the ongoing battle against MRSE biofilms.  
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Chapter 5: BPEI potentiates ampicillin against MRSA biofilms 
Background 
Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a serious 
threat worldwide. MRSA is the predominant species isolated from medical-device-
related biofilm infections and chronic wounds. Its ability to form biofilms grants it 
resistance to almost all antibiotics on the market. Answering the call for alternative 
treatments, our lab has been investigating the efficacy of 600 Da branched 
polyethylenimine (BPEI) as a β-lactam potentiator against bacterial biofilms. Our 
previous study showed promise against methicillin-resistant Staphylococcus 
epidermidis biofilms. This study extends our previous findings to eradicate a more 
virulent pathogen – MRSA biofilms. Microtiter minimum biofilm eradication 
concentration models, crystal violet assays, and electron microscopy images show 
synergistic effects between BPEI and ampicillin as a two-step mechanism: step one is 
the removal of the extracellular polymeric substances (EPS) to expose individual 
bacteria targets, and step two involves electrostatic interaction of BPEI with anionic 
teichoic acid in the cell wall to potentiate the antibiotic. 
Prevalence and Pathogeneses 
The threat posed by antimicrobial resistance (AMR) on human health is well 
known. We recently reported that 600-Da BPEI eliminates β-lactam resistance in 
methicillin-resistance Staphylococcus aureus (MRSA) by preventing the essential 
localization of PBP4 enzymes.119 However, the sinister nature of AMR infections is 
amplified when the pathogens are sequestered in biofilms that shield them from effective 
antimicrobials and/or the innate immune system. According to a systematic review and 
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meta-analysis,120 the prevalence of biofilms in chronic wounds is almost 80%. Many of 
the predominant species found in chronic wounds are from the genus Staphylococcus 
(~60%).94 In addition to compromising wound healing,121 Staphylococcus aureus 
contributes a high percentage to biomedical device infections.65 Bacterial biofilms are 
resilient because their self-produced matrix of extracellular polymetric substances (EPS) 
grants them protection against host defenses and antibiotics.92, 110, 117 The EPS matrix 
contains hydrated carbohydrate polymers, proteins, and extracellular DNA (eDNA) in a 
complex architecture to provide nutrients, promote the transfer of genetic material, and 
protect the biofilm against harsh conditions. Only the outer-most layers of cells in a 
biofilm are metabolically active, while the persistent inner-layer cells remain dormant, 
thereby evading antibiotics.117 First-line β-lactam antibiotics , such as ampicillin, are the 
most commonly prescribed drugs for bacterial infections. In many developing countries, 
these antibiotics are sold over the counter, and their use in livestock is poorly regulated. 
Lack of regulation can lead to overexposure, thereby encouraging acquired antimicrobial 
resistance. As the most common agricultural pathogens in developing countries, AMR 
has a convenient means of spreading to humans.13 According to the CDC, MRSA 
infections pose a grave threat to the society and economy.122 One out of seven severe 
cases of MRSA results in death.123 Its resistance has been documented within all available 
antibiotic classes, including the last-resort antibiotics.15 With a dwindling collection of 
new antibiotics and in the absence of antibiofilm drugs on the market, alternative 
treatments that combine existing drugs with potentiators have become a central line of 
research. Here, we demonstrate the ability of 600 Da branched polyethylenimine (BPEI) 
to eradicate MRSA biofilms. Our previous studies have shown that this low-molecular-
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weight BPEI exhibits low in vitro cytotoxicity on human cells,45 and strong potentiation 
with β-lactam antibiotics against planktonic MRSA cells.45, 68 Strong synergy was also 
found against methicillin-resistant Staphylococcus epidermidis (MRSE) and its 
biofilms.1-2 Thus, we hypothesize that BPEI would potentiate ampicillin against MRSA 
biofilms using similar biochemical mechanisms.  
Gram-positive bacteria, such as S. aureus and S. epidermidis, have a thick 
peptidoglycan layer in their cell walls. For each division cycle, penicillin-binding proteins 
(PBPs) are responsible for one of the last stages of cell wall synthesis: cross-linking the 
subunits of the peptidoglycan. β-lactam antibiotics irreversibly bind to PBPs, preventing 
them from performing this vital function. Consequently, the bacteria are unable to divide 
and eventually burst from excessive cytoplasmic pressure. However, in MRSA/MRSE, 
the enzymes PBP2a and PBP4 with low binding affinity to β-lactams allow the bacteria 
to withstand the antibiotic attack. An important regulator of PBP2a/4 is wall teichoic acid 
(WTA) that is decorated with N-acetylglucosamine, D-alanine, and hydroxyl on a 
phosphodiester backbone.61, 124 The phosphates impart strong anionic properties to WTA 
and consequently WTA attracts essential metal ions to the cell wall environment.40, 125-128 
However, we have shown that the anionic nature of WTA can be exploited to circumvent 
the PBP2a/4 enzymes responsible for β-lactam resistance in MRSA. 600-Da BPEI, a 
small cationic polymer, electrostatically binds to anionic WTA in the bacterial cell wall, 
thus prohibiting WTA from properly localizing PBP2a/4 enzymes. This process 
effectively potentiates β-lactams against planktonic MRSA45, 68, 119 and MRSE.1-2 As 
described below, we extend the investigation of 600-Da BPEI potentiators to MRSA 
biofilms and demonstrate strong efficacy against two biofilm-forming MRSA clinical 
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isolates (MRSA OU6 and OU11) that are strongly resistant to antibiotics. (clinical data 
are shown in Table 4) 
Table 4: MRSA clinical isolates susceptibility data 
 
Purpose of Experiment 
The purpose of this experiment is to determine the synergy of 600-Da BPEI and 





In this experiment, the Staphylococcus aureus (MRSA 43300) was purchased from the 
American Type Culture Collection. Two MRSA clinical isolates (MRSA OU6 & OU11) 
from patient swabs were kindly provided by Dr. McCloskey from the University of 
Health Sciences Center with an institutional review board (IRB) approval. Chemicals 
(DMSO, growth media, and electron microscopy fixatives) were purchased from Sigma-
Aldrich. Antibiotics (ampicillin and polymyxin B) were purchased from Gold 
Biotechnology. 600 Da BPEI was purchased from Polysciences. MBEC™ Biofilm 
Inoculators were purchased from Innovotech. Isopore polycarbonate membrane filters 
(0.1 µm pore size, hydrophilic, 13 mm diameter) were purchased from MilliporeSigma. 
MBEC Assay  
This method is adapted from our previous study.2 In brief, bacterial culture was 
inoculated in an MBEC pronged-inoculator and incubated for 24 hr to allow biofilm 
formation. Then, the preformed biofilm prong lid was washed and treated in a separate 
challenge plate which was prepared as a checkerboard assay:1 serial dilutions of BPEI 
and antibiotic solutions were added to a 96-well base plate with a total volume of 200 µL 
cation-adjusted Muller Hinton broth (MHB) per well. The change in optical density at 
600 nm (Δ OD600) was measured. Minimum inhibitory concentration (MIC) of each drug 
is determined as the lowest concentration that inhibited cell growth (ΔOD600 < 0.05). 





. Synergistic effects are determined using EUCAST guidelines: synergy (FICI ≤ 
0.5), additivity (0.5 < FICI < 1), and indifference (FICI > 1).62 The treated pronged-
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inoculator was then washed and transferred to a recovery plate with 200 µL MHB/well 
to sonicate and recover any remaining biofilm bacteria. The recovery plate was then 
incubated overnight before measuring ΔOD600 to determine MBECs and FICIs of the 
drugs tested on the biofilms. 
Biofilm Disrupting Assay 
This method is also described in details by Lam et al.2 This experiment was 
parallelly conducted with polymyxin B (PmB, a cationic polypeptide antibiotic) and 
BPEI. In short, an overnight MRSA OU 6 culture was inoculated in a tissue-culture 
treated 96-well plate (100 µL of tryptic soy broth or TSB/well) with an inoculation size 
of 1 µL/well (~5 x 105 CFU/mL). The plate was incubated at 35 oC for 24 hr to allow the 
bacteria to form biofilm. It was then washed with water to remove planktonic bacteria 
and stained with 100 µL of crystal violet solution (0.1%) per well for 15 min. The stained 
plate was washed excessively with water 5 times to remove any unbound stain and air-
dried overnight. Vary concentrations of PmB (64 and 128 µg/mL) and 600 Da BPEI (64 
and 128 µg/mL) were added to the stained-biofilm plate with a total volume of 100 
µL/well. A negative control (water only) and positive control (30% acetic acid) were also 
conducted at the same time of treatment. After 20 hr, without touching the biofilm layer 
in the bottom of the plate, solubilized solution in each treated well was carefully 
transferred to a new 96-well plate for an OD550 measurement, which represents the 
corresponding amount of biofilm disrupted by each treatment.  
Scanning Electron Microscopy (SEM) 
MRSA OU6 were inoculated from 0.5% of an overnight culture on glass 
coverslips and grown at 35 °C. After 24 hr. the biofilm-formed on glass coverslips were 
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carefully removed and washed in water for 10 s. Then each sample was submerged in 
different treated solution (untreated control, 128 µg/mL BPEI-treated, and bleach-
positive control) for another 24 hr. Next, they were removed, washed in water for 10 s, 
and submerged in primary fixative (5% glutaraldehyde in 0.1 M cacodylate buffer) and 
incubated at 4 ± 2 °C for 2 days. The glass coverslips were removed from the fixing 
solution and air-dried for 72 hr. They were mounted on aluminum stubs with carbon tape 
and sputter-coated with AuPd. A Zeiss NEON SEM was used to image the samples at 5 
kV accelerating voltage.  
SEM of Biofilms on Polycarbonate Membrane Filters 
 Pre-sterilized polycarbonate (PC) membranes were gently adhered to a tryptic 
soy agar plate using sterilized forceps. A volume of 2 µL of the stock MRSA OU6 
solution (~5 x 105 CFU/mL) was pipetted on top of each PC membrane and incubated at 
35 °C for 7-8 hr, when the MRSA biofilm colony on the PC membranes became visible 
to the naked eye.  
 
The PC membranes with preformed biofilm was then carefully removed off the agar, 
transferred into a treatment solution of 256 µg/mL BPEI, and incubated for another 20 
hr. Untreated and treated PC samples were removed and washed in water for 10 s. They 
were submerged in primary fixative (5% glutaraldehyde in 0.1 M cacodylate buffer) and 
incubated at 4 ± 2 °C for 2 days. The PC samples were air-dried slowly for 3 more days. 
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They were mounted on aluminum stubs with double-side carbon tape, sputter-coated 
with AuPd, and imaged at 5 kV accelerating voltage by a Zeiss Neon SEM.  
Results and Discussion 
Minimum biofilm eradication concentration (MBEC) assays were utilized on the 
two clinical isolates of MRSA (OU6 and OU11) and a lab strain MRSA ATCC 43300. 
The MRSA bacteria are used to inoculate a 96-well inoculation plate, where MRSA 
biofilms were grown on prongs protruding from the plate lid, known as the MBEC 
inoculator lid and based on the Calgary biofilm device. The inoculator lid was washed to 
remove unattached MRSA cells and transferred into a separate 96-well base for treatment 
with BPEI and ampicillin combinations arranged in a checkerboard assay pattern, the so-
called the challenge plate. The final step is moving the treated inoculation lid to a third 
plate (the recovery plate) containing growth-media only and using sonication to dislodge 
the biofilm and recover cells remaining in the biofilm.  In this manner, we are able to 
evaluate the synergy of BPEI and ampicillin against MRSA biofilms. Standard CLSI 
(Clinical & Laboratory Standards Institute) guidelines describe a standard MIC assay 
using 96-well plates inoculated with a standard cell density, usually ~106 CFU/mL. 
However, the MIC data reported here is non-standard because, rather than inoculation via 
micropipette transfer from an overnight culture, inoculation of the challenge plate occurs 
from the biofilm-coated inoculation lid where treatment challenge disrupts the protective 
biofilm EPS matrix. MRSA cells are dislodged and dispersed into the challenge plate 
media. These cells in the challenge plate media are susceptible to killing by the 600-Da 
BPEI, ampicillin, or their combinations and a minimum inhibitory concentration can be 
determined. We refer to this value as MICCP to differentiate it from MIC measurements 
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made with standard methods. The MBEC is determined from cell growth in the recovery 
plate and reflects the ability of 600-Da BPEI, ampicillin, or its combinations to kill the 
biofilm remaining attached to the prongs of the inoculation lid. The MICCP and MBEC 
data are shown for comparison (Table 5). 
Table 5. Synergistic effects between BPEI and ampicillin against MRSA biofilms 
Strain 
BPEI (µg/mL) Ampicillin (µg/mL) 
FICI Synergy? 
MICCP MBEC MICCP MBEC MBEC + 64 µg/mL BPEI 
MRSA 
43300 64 >256 128 >256 2 0.13 
yes 
MRSA 
OU6 >256 >256 256 >256 64 0.25 
yes 
MRSA 
OU11 >256 >256 128 >256 32 0.19 
yes 
 
As shown in Table 5, MRSA 43300s BPEI MBEC (>256 µg/mL) is much larger 
than its MICCP (64 µg/mL). Similarly, the ampicillin MBEC (>256 µg/mL) is higher than 
the corresponding MICCP (128 µg/mL). The MBECs for BPEI and ampicillin against the 
two clinical isolates, MRSA OU6 and OU11, are greater than the highest amount tested, 
256 µg/mL. Although the MBECs exceeded the tested concentrations, strong synergy 
(FICI < 0.5) was found between BPEI and ampicillin against the biofilms of MRSA 
43300, OU11, and OU6 with an FICI of 0.13, 0.25, and 0.19, respectively. For example, 
when combined with 64 µg/mL of BPEI, the ampicillin MBECs for MRSA 43300, OU6, 
and OU11 were reduced to 2, 64, and 32 µg/mL, respectively. For these strains, the MICCP 
is higher than previously reported values for planktonic MRSA cells evaluated with CLSI 
methods,119 which showed that 600-Da BPEI lowers the MIC for the planktonic cells and 
renders them susceptible to oxacillin. As described above, the disparity arises from 
different methods of inoculation and the cell density in the challenge plate media is 
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unknown and likely varies between wells. Nevertheless, the  MICCP can be used to show 
that BPEI and ampicillin combinations can be used to kill antibiotic-resistant cells 
dislodged from the inoculation lid. 
Heatmaps of the average checkerboard results are shown in Figure 30. Data used 
to determine MICCP in the challenge plate containing MRSA planktonic data are shown 
on the left (Figure 30Ai, Bi, and Ci) and the corresponding biofilm data are on the right 
(Figure 30Aii, Bii, and Cii). As expected, the MBECs are larger than the respective 
MICCP values. This demonstrates the intrinsic protective nature of biofilms against 
antimicrobial agents. The stair-case pattern found in the heatmaps indicate synergy of 
BPEI and ampicillin against both planktonic and biofilm forms of MRSA 43300, OU6, 
and OU11 strains. As BPEI concentration increases, the required MICCP and MBEC 
values of ampicillin decrease to achieve high inhibition percentage, highlighting the 




Figure 30. Synergy between BPEI and ampicillin against MRSA 43300 (A), MRSA OU6 
(B), and MRSA OU11 (C). Checkerboard assay data on planktonic bacteria are shown on 




To better elucidate the antibiofilm activity of BPEI, biofilm disruption assays were 
conducted along with a comparison study using the common cationic antibiotic 
polymyxin B. Briefly, MRSA OU6 biofilms were grown on the bottom of a 96-well plate 
for 24 h. After repeated washing, the biofilms were stained with crystal violet for 
semiquantitative analysis. The biofilms were then treated to investigate the ability of 
BPEI or polymyxin-B to disrupt the biofilm. As shown in Figure 31, the negative control 
of water only had no impact on disrupting the MRSA biofilms because the biofilm layer 
remained intact in the bottom (top-down photographic image in Figure 31A). On the other 
hand, 600 Da BPEI (64 and 128 μg/mL) completely dispersed the MRSA biofilms into 
its solution in a manner similar to that of the positive control, acetic acid. However, 
exposure to polymyxin B, a U.S. Food and Drug Administration (FDA)-approved 
cationic polypeptide antibiotic, resulted in a slight dissolution in biomass, although 128 
μg/mL was more effective than 64 μg/mL. The biofilm-disrupting properties are 
quantitatively reported as OD550 measurements of the amount of biofilm dislodged 
(Figure 31B). This demonstrates BPEI’s ability to eradicate MRSA biofilms by forcing 
them to detach and disperse its bacterial cells into planktonic culture, where they 
transition from a persistent quiescent state into a metabolically active realm and thus 




Figure 31. Established MRSA OU6 biofilms stained with crystal violet were treated with 
polymyxin B (PmB) and 600 Da BPEI for 20 hours, as well as the negative control (water 
only) and positive control (30% acetic acid). The dissolved biofilm solutions were 
transferred to a new plate, and the biofilm remainders are shown as top-down view, (A). 
The mean OD550 of the dissolved biofilm solution was measured, (B). Error bars denote 
standard deviation (n = 10).  
To better characterize the effect of BPEI on MRSA biofilms, morphological 
analysis was performed using scanning electron microscopy (SEM). Twenty-four hr-
established MRSA biofilms on glass coverslips were treated with 128 µg/mL of BPEI. 
An untreated control and the BPEI-treated samples were then fixed and imaged with 
SEM. As shown in Figure 32A and 32C, the untreated control MRSA biofilm is enclosed 
in a thick coat of EPS. Like all biofilm-forming bacteria, the EPS is their self-made 
protection against harsh environments and antibiotics. With BPEI treatment, the 
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preformed MRSA biofilm lost most of its EPS coat (Figure 32B). At higher magnification 
(Figure 32D), the lack of EPS in the treated sample rendered the inner layers of the 
bacteria—which were hidden in the untreated control—visible. To mimic a wound 
environment, MRSA biofilms were grown on polycarbonate (PC) membrane filters (0.1 
µm pore size) placed directly only tryptic soy agar. The membrane pores allow for 
nutrient absorption and we found that these biofilms are more robust than those grown on 
glass slides. In the untreated control sample (Figure 33A), the EPS is so thick that the 
SEM scan cannot locate the bottom of the PC membrane filter. In BPEI-treated sample 
(Figure 33B), many areas are exposed from the absence of EPS, including the bottom 
surface of the membrane filter whose nano-size pores (tiny white dots through the crack 
in Figure 33B) are clearly visible. 
 
Figure 32. SEM images of MRSA OU11 biofilms on glass coverslips. Untreated control 
biofilms are shown to be covered and wrapped around in the matrix of EPS (A and C). 
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BPEI-treated samples have much less EPS with many cells being exposed (B and D). 
Scale bars in A and B = 2 µm. Scale bars in C and D = 1 µm. 
 
Figure 33. SEM images of established MRSA OU6 biofilms on PC membranes. Very 
thick coat of the EPS matrix is present in the untreated control biofilm on the PC 
membrane which also blocks the bacterial cells from being captured in the microscope 
(A). BPEI-treated sample has a much clearer view as the EPS removed and even the 
membrane surface is exposed as many nano-size pores are seen at the bottom (B). Scale 
bars in A and B = 1 µm.  
The biofilm EPS of S. aureus contains a high fraction of polysaccharide 
intracellular adhesin (PIA) and anionic species that are prime targets for 600 Da BPEI 
binding, such as eDNA and extracellular teichoic acid (TA). The latter is a key component 
in the biofilm EPS matrix of S. epidermidis31 and S. aureus.117, 129 It enhances bacterial 
adhesion to biotic and artificial surfaces, which is the first step of biofilm formation. TA 
has a negative net charge at neutral pH because it contains more negatively-charged 
phosphates than positively-charged D-alanine residues.129 Using nuclear magnetic 
resonance spectroscopy, we found that 600-Da BPEI electrostatically binds wall teichoic 
acid, which indirectly hinders the resistance factor PBP2a/4.68 Similarly, BPEI most 
likely binds extracellular TA in the EPS matrix, and also eDNA, to disrupt biofilm 
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structural integrity, as seen in Figure 32 and 33. The exposure of individual bacteria could 
enhance their contact with various drugs and components of the immune system. 
Conclusion 
Skin or soft-tissue infections (SSTIs) arise from abrasions, nonsurgical wounds, 
burns, or chronic health problems.130 For chronic wound infections associated with 
MRSA and its biofilm, treatment options are scarce. Patients afflicted with these chronic 
wounds suffer from physical pain and disabilities in addition to psychological and 
emotional stresses and poor quality of life. Current inpatient treatments include cleansing, 
debridement, maintaining a moist tissue environment, and, when possible, eliminating 
the underlying pathology or factors that contribute to poor wound healing.131 In advanced 
cases, amputation may become necessary. Death, especially in elderly patients, may result 
from sepsis that can be associated with chronic wounds. Antibiotics can be used 
effectively against susceptible infections. For drug-resistant infections, the best practices 
for effective inpatient intervention are strict sanitary guidelines and antibiotics, such as 
intravenous vancomycin plus piperacillin/tazobactam or IV treatment with new 
antibiotics of last resort.131 Nevertheless, biofilms and antimicrobial resistance create 
substantial technological barriers to treating chronic wound infections. This presents a 
significant and critical need for a way to counteract biofilms and antimicrobial resistance. 
The 600 Da BPEI is a dual-function potentiator because it disrupts biofilms that are 
otherwise impenetrable to antibiotics, and also it counteracts β-lactam resistance 
mechanisms in MRSA However, success requires that 600 Da BPEI have low toxicity. 
In dermal applications, low-molecular-weight BPEI was shown to have high 
biocompatibility and low genotoxic potential.107 We also confirmed the non-cytotoxicity 
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of 600 Da BPEI toward human kidney, colon, and HeLa cells by using in vitro 
nephrotoxicity assays.45, 68 Additional experiments are planned to determine 600 Da 
BPEI’s toxicity levels in dermal and subcutaneous layers. With bacterial evolution 
outpacing the discovery of antimicrobial agents, it is imperative to seek alternative 
treatments options, such as coupling existing drugs with potentiators. With a dual-
function mechanism that eliminates antibiotic efficacy barriers in both planktonic and 
biofilm-encased bacteria, 600 Da BPEI has promise as a therapeutic agent for improving 
wound care and combating medical device infections. Potency of first-line antibiotics 
such as ampicillin can now be restored by the addition of BPEI against drug-resistant 
MRSA, as seen by their strong synergistic effects. Combinations of BPEI and antibiotics 
could be administered to diagnosed or suspected staph-biofilm infections, which would 
improve the efficacy of treatment of resistant, biofilm-forming pathogens.   
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Chapter 6: Broadening the spectrum of antibiotics capable of killing 
multidrug-resistant Staphylococcus aureus and Pseudomonas 
aeruginosa 
Background 
Infections from drug-resistant superbugs, such as methicillin-resistant 
Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are a serious threat 
because reduced antibiotic efficacy complicates treatment decisions and prolongs the 
disease state in many patients. To expand the arsenal of treatments against antimicrobial 
resistance (AR) pathogens, 600-Da branched polyethylenimine (BPEI) can overcome 
antibiotic resistance mechanisms and potentiate β-lactam antibiotics against Gram-
positive bacteria. BPEI binds cell wall teichoic acids and disables resistance factors 
from penicillin binding proteins PBP2a and PBP4. The present study describes a new 
mechanism of action for BPEI potentiation of antibiotics generally regarded as agents 
effective against Gram-positive pathogens but not Gram-negative bacteria. 600-Da 
BPEI is able to reduce the barriers to drug influx and facilitate the uptake of a non-β-
lactam co-drug, erythromycin, that targets the intracellular machinery. Also, BPEI can 
suppress cytokine interleukin IL-8 release from human epithelial keratinocytes. This 
enables BPEI to function as a broad-spectrum antibiotic potentiator which expands the 
opportunities to improve drug design, antibiotic development, and therapeutic 
approaches against pathogenic bacteria, especially for wound care. This study was 
published in ChemMedChem Journal.3  
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Bacterial Membranes and The Non-β-Lactam Antibiotics 
Crossing the bacterial membrane is a difficult task for many antimicrobial drugs 
that must reach their intracellular targets of Gram-positive and Gram-negative bacteria. 
Improving antibiotic efficacy can be accomplished with potentiation adjuvants 
comprising a vast array of different compounds and targets.132-140 A common theme is 
weakening the cell envelope framework. The outermost portions of the cell envelope of 
Gram-negative and Gram-positive bacterial pathogens are under exploited weaknesses 
in antimicrobial resistance mechanisms.61, 141-144 Many efforts are focused on inhibitors 
to the cytoplasmic expression and/or the membrane translocation of essential proteins, 
enzymes, and precursors required for the assembly of molecules required for the cell-
envelope machinery and architecture. These approaches may suffer from deleterious 
protein binding effects or have low solubility from hydrophobic properties necessary to 
cross the membrane barriers. Likewise, methods to overcome resistance are different 
depending on whether the pathogen is a Gram-positive or Gram-negative bacterium. 
The divergent approaches to overcome resistance arise from the intrinsic nature 
of bacterial cell walls and their differing mechanisms of antibiotic resistance. The 
cytoplasm of Gram-positive bacterial cells is surrounded by a single phospholipid 
bilayer and this membrane is surrounded by a thick layer of peptidoglycan interlaced 
with anionic teichoic acids. However, the phospholipid membrane of Gram-negative 
bacteria is encased by a periplasm region that contains a thin peptidoglycan layer 
attached to an asymmetric outer membrane bilayer (Figure 34). The inner leaflet of the 
outer member contains phospholipids, but the outer leaflet contains lipopolysaccharides. 
Together, these layers comprise a formidable barrier to the influx and/or diffusion of 
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antibiotics into the periplasm and cytoplasm to reach their drug targets. Approaches to 
disable resistance from β-lactamase enzymes and efflux pumps, such as using 
inhibitors, are often tailored for Gram-negative bacteria, such as multi-drug resistant 
Pseudomonas aeruginosa (MDR-PA), and rarely work against Gram-positive bacteria 
that lack these primary resistance mechanisms. Resistance in Gram-positive bacteria, 
for example methicillin-resistant Staphylococcus aureus (MRSA), is dominated by 
alternative means to continue the assembly and synthesis of peptidoglycan; thereby 
bypassing the activity of β-lactams.  
 
Figure 34. Graphical presentation of 600-Da BPEI’s mechanisms of action on Gram-
positive and Gram-negative cell wall and membrane. Cationic BPEI not only binds 
anionic wall teichoic acid (WTA) to indirectly disable penicillin binding proteins 
PBP2a/4 (which only function properly by localization of WTA), it also electrostatically 
binds the phosphate heads of the lipid membrane, causing a partial loss of the 
permeability barrier. Consequently, BPEI can potentiate both β-lactams and non-β-
lactams (those target intracellular machinery) against MRSA (Gram-positive). In 
Pseudomonas (Gram-negative), BPEI binds anionic LPS, creating new hydrophilic 




First-line antibiotics include the β-lactam class of antibiotics, considered among 
the safest antibiotics to use.145-148 In 2015, the US had 269.3 million antibiotic 
prescriptions given by healthcare providers, which is equivalent to 838 prescriptions per 
1000 people. Among them, β-lactams (i.e. penicillin, oxacillin, and amoxicillin) were 
the most popular prescribed antibiotics with amoxicillin at the top of the chart at 171 
prescriptions per 1000 people.28 Although MRSA is β-lactam resistant, disabling 
penicillin binding protein PBP2a and PBP4 renders MRSA susceptible. We reported 
that cationic 600-Da branched polyethylenimine (600-Da BPEI) accomplishes this 
objective by interacting with wall teichoic acid (WTA) that is essential for PBP2a/4 
functionality.1, 45, 68, 119 For those with penicillin allergies, erythromycin and other 
broad-spectrum macrolides are prescribed as standard of care antibiotics, but clinical 
isolates of MRSA do not respond to erythromycin treatment. Here, we show that MRSA 
clinical isolates with erythromycin resistance can be rendered drug-susceptible when 
600-Da BPEI is used to reduce the barriers to drug-influx. Importantly, we also show 
that 600-Da BPEI potentiates erythromycin against clinical isolates of MDR-PA. This is 
noteworthy because erythromycin is regarded as an antibiotic without efficacy against 
Gram-negative bacteria, including those without antimicrobial resistance. The 
mechanism of action (MOA) involves binding with anionic sites of the bacterial cell 
envelope (lipopolysaccharide (LPS), wall teichoic acid (WTA), lipoteichoic acid 
(LTA)) to create new hydrophilic conduits for erythromycin to reach the cytoplasm 
(Figure 34). 600-Da BPEI is hydrophilic and targets anionic sites on the cell envelope 
away from the alkyl chains of membrane bilayers. It reduces diffusion barriers to 
increase drug uptake and enables broad-spectrum efficacy against different bacterial 
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species. Instead of acting as an antimicrobial agent itself, low concentrations of 600-Da 
BPEI potentiate the efficacy of erythromycin against clinical isolates of MRSA and 
MDR-PA. Additionally, BPEI reduces interleukin-8 (IL-8) cytokine’s release from 
primary human epithelial keratinocytes (HEKa) cells, suggesting another therapeutic 
application for wound care. These data also show that improving the efficacy of 
standard of care antibiotics, such as β-lactams and macrolides, against AMR Gram-
positive and Gram-negative, bacteria creates new opportunities to improve patient 
health and well-being. 
Purpose of Experiment 
The purpose of this experiment is: to investigate a new mechanism of action of 
600-Da BPEI in broadening the spectrum of erythromycin antibiotic against multidrug-
resistant (MDR) Staphylococcus aureus and MDR-Pseudomonas aeruginosa; and to 
examine the ability of BPEI in reducing interleukin-8 (IL-8) cytokine’s release from S. 
aureus peptidoglycan on primary human epithelial keratinocytes (HEKa) cells. 
Experimental Procedures 
Materials 
Two MRSA clinical isolates (MRSA OU6 and MRSA OU11) and P. aeruginosa 
(PA OU19) from patient swabs were kindly provided by Dr. McCloskey from the 
University of Health Sciences Center with an institutional review board (IRB) approval. 
Chemicals (DMSO, growth media, erythromycin, polymyxin B, H33342 dye, and 
peptidoglycan from Staphylococcus aureus (product number 77140) were purchased 
from Sigma-Aldrich. 600-Da BPEI was purchased from Polysciences. HEKa cells 
(primary human epithelial keratinocytes), Epilife Medium, and growth supplement were 
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purchased from Invitrogen. Human IL-8/CXCL8 Quantikine ELISA Kit was purchased 
from R&D.  
In Vitro Checkerboard Assay 
Checkerboard assays were conducted to identify synergy between BPEI and 
antibiotics against bacteria. Serial dilutions of antimicrobial agents (BPEI and antibiotic 
solutions) were added to a 96-well microtiter plate with 100 µL cation-adjusted Muller 
Hinton broth (CAMHB) per well. Untreated control and positive control (5% bleach) 
were also conducted. Bacterial inoculation (5 x 105 CFU/mL) from an overnight culture 
was added to the plate (1 µL/well) and incubated at 37°C for 20 hr. The change in optical 
density at 600 nm (ΔOD600) was measured using a Tecan Infinite M20 plate reader 
immediately after inoculation. Minimum inhibitory concentration (MIC) of each drug is 
determined as the lowest concentration that inhibited cell growth (ΔOD600 < 0.05). 
Fractional inhibitory concentration index (FICI) and synergistic effects are determined 
using EUCAST guidelines: synergy (FICI ≤ 0.5), additivity (0.5 < FICI < 1), and 
indifference (FICI > 1).62 Each assay was done in triplicate. 
Cell-permeation Assay / bisBenzimide H33342 Intracellular Accumulation 
Cryogenic stock of bacteria (MRSA OU6, OU11, MRSE 35984, or PA OU19) 
was inoculated overnight on tryptic soy agar. The culture was sub-inoculated in fresh 
tryptic soy broth (TSB) media for another 5-6 hours with shaking (100 rpm/min). Cells 
were pelleted by centrifugation at 7000 rpm for 40 min. The supernatant was discarded. 
The cells were resuspended in PBS and readjusted to OD600 = 1.0. (which had a density 
of ~7 x 109 CFU/mL). Aliquots of the cell suspension were transferred to a 96-well flat-
bottom black plate (180 µL/well) including the controls of the solvent (PBS blank), the 
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untreated cells, and treated samples (either BPEI treated or polymyxin-B treated). Five 
technical replicates of each group were conducted. Hoechst 33342 bisbenzimide 
(H33342) was added (20 µL) to each well (final concentration of 5 µM). Fluorescence 
was read right after adding the H33342 by a Tecan Infinite M20 plate reader with the 
excitation and emission filters of 355 and 460 nm, respectively. Fluorescence data were 
normalized to the emission before cells were added in the PBS control, and they were 
plotted against time to show the cellular uptake of H33342 over 10 min.  
Cell viability assays 
 with resazurin were performed with MRSA OU11 cells were grown in TSB as 
similar to the procedure of cell-permeation assays until they reach a density of ~7 x 109 
CFU/mL. Then the cell culture was transferred into a 96-well plate (100 µL/well) for 
BPEI or polymyxin B (PmB) treatments at varied concentrations from 64 - 512 µg/mL. 
Controls of untreated and positive control of 5% bleach were also conducted. The plate 
was incubated at 37°C overnight. Resazurin (50 µL; final concentration of 50 µg/mL) 
was then added and, after 1 hour of incubation, the fluorescence intensity was measured 
(λex = 560 nm; λem = 590 nm). 
IL-8 responses 
HEKa cells were seeded in T-75 tissue culture flasks with Epilife media 
supplemented with human keratinocyte growth supplement 100ug/mL and 100 U/mL of 
pen/strep and incubated at 37°C in a CO2 incubator. Fresh media was replaced every 2 
days. Until the cell confluence reach 80-90%, they were split into a new passage. To 
avoid cell senescent, all experiments were performed with cells at passage 3-7. HEKa 
cells were cultured in a new 24-well plate until 80-90% confluence (total volume = 1 mL/ 
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well). Then treatments of 600-Da BPEI (64, 128, 256, 512, and 1024 µg/mL) or S. aureus 
peptidoglycan (5 µg/mL) were added in triplicate cultures for 24 hr. The cell media was 
collected in 1.5 mL Eppendorf microtubes and stored at -20°C until ELISA assays were 
performed. Concentrations of IL-8 cytokine released into the media were quantified 
followed the instructions of Quantikine Colorimetric ELISA assay kits (R&D Systems). 
Absorbance was measured at 450 nm and 570 nm. Final corrected absorbance was the 
subtraction at 450 nm from the one at 570 nm. 
 
Results and Discussion 
Since the 1950s, erythromycin—a macrolide antibiotic—has been widely used as 
a substitute for β-lactams for penicillin-allergic patients. It is a first-line treatment for 
many pediatric infections.149 Because erythromycin targets protein synthesis instead of 
the cell wall, it could be effective against methicillin-resistant staphylococci if the drug 
was able to reach the cytoplasm. The ability of 600-Da BPEI to increase erythromycin 
susceptibility was determined with in vitro checkerboard assays in 96-well microtiter 
plates. For two clinical MRSA isolates, their erythromycin MICs were over 2000 μg/mL 




Figure 35. Absorbance (OD.600) of erythromycin (eryth) MIC scan on MRSA OU6 and 
OU11 shows that the two bacterial strains had high resistance to erythromycin (both MICs 
are over 2000 µg/mL since no inhibitory effect was found; n = 3). 
This demonstrates the strong resistance of MRSA, likely imposed by cell wall 
peptidoglycan and teichoic acids that hinder drug influx. However, 600-Da BPEI binds 
to these sites1, 45, 68, 119 and improves the MRSA susceptibility to erythromycin. The MIC 
is reduced by 2-3 orders of magnitude in the presence of 16 μg/mL of 600-Da BEPI 
(Figure 36 and Table 6). This broadens the spectrum of potential anti-MRSA drugs 
because, as previously reported,4, 119 600-Da BPEI was able to eliminate only β-lactam 
resistance in these MRSA isolates and their biofilms. Against the MDR-PA clinical 
isolate OU19, 16 μg/mL BPEI lowers the erythromycin MIC from 256 to 2 μg/mL (Figure 
36 and Table 6). This demonstrates antibiotic potentiation against a formidable Gram-
negative pathogen. As shown in Figure 35, potentiation by 600-Da BPEI relies on its 
interaction with different bacterial targets due to the different cell envelope architecture 
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of MRSA and MDR-PA. Nevertheless, 600-Da BPEI can overcome both resistance 
barriers, and erythromycin potentiation by 600-Da BPEI is characterized as synergistic 
(Table 6). According to the EUCAST guidelines, a fractional inhibitory concentration 
index (FICI) is used to identify synergistic effects. FICI values can indicate synergy (FICI 
≤ 0.5), additivity (0.5 < FICI < 1), or indifference (FICI ≥ 1).62 Erythromycin and 600-
Da BPEI have synergy against MRSA (FICI = 0.26 for OU6, 0.31 for OU11) and MDR-
PA OU19 (FICI = 0.26). 
 
Figure 36. Checkerboard data presentation of bacterial growth inhibition from the 
combination of erythromycin and 600-Da BPEI.  The MICs in these checkerboard 
assays can be used to show synergy in the clinical isolates MRSA OU6 (A), MRSA 
OU11 (B), and PA OU19 (C). Each assay was performed in triplicate and the data 
presented above are the average of these assays. 
Table 6. Synergy of 600-Da BPEI and antibiotics against MRSA and MDR-PA 
clinical isolates 












Erythromycin 64 >2000 8 0.26 Synergy 
MRSA 
OU11 Erythromycin 64 >2000 128 0.31 Synergy 
PA 
OU19 Erythromycin 64 256 2 0.26 Synergy 
[a] MIC, Minimum Inhibitory Concentration; [b] FICI, the minimum Fractional Inhibitory Concentration Index 
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Synergy between 600-Da BPEI and erythromycin is attributed to increase drug 
influx. Resistance to non-β-lactam antibiotics (such as macrolides, tetracyclines, and 
fluoroquinolones) involves membrane-bound efflux-pump proteins. These protein 
assemblies eject toxic substances (i.e. antibiotics), hindering accumulation of antibiotics 
in the bacterial cells.150-152 To examine increased drug influx, we tested the ability of 600-
Da BPEI to increase the intracellular concentration of a fluorescence probe molecule,  
Hoechst 33342 bisbenzimide (H33342). H33342 fluoresces when it penetrates the cell-
membrane and binds to intracellular DNA. Greater accumulation of H33342 in the cells 
creates a higher fluorescence intensity. Fluorescence measurements were taken for 
untreated and BPEI-treated samples immediately after adding the H33342 dye. 
Figure 37. H33342 permeation curves show the addition of BPEI (128 µg/mL) 
enhances the cell-membrane permeability of MRSA OU6 and OU11 as the fluorescence 
of H33342 increased, compared to their untreated control. Error bars denote standard 
deviation (n = 5). 
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As shown in Figures 37, 600-Da BPEI enhanced dye uptake in MRSA OU6 and 
MRSA OU11. The BPEI-treated cells had much higher fluorescence intensity by 
approximately 10,000 fluorescence units compared to their untreated controls. Similar 
trends are observed for the influx of H33342 into cells of the MDR-PA clinical isolate 
OU19 (Figure 38). P. aeruginosa is well-known for a powerful drug-efflux system and 
thus the low accumulation of H33342, compared to Gram-positive MRSA, is not 
unexpected. Nonetheless, as with MRSA, 600-Da BPEI increases the uptake of H33342 
in PA OU19. 
 
Figure 38. H33342 permeation curves show the addition of of 128 µg/mL polymyxin B 
(PmB) drastically increases the dye uptake more than twice of that 128 µg/mL BPEI 




The concentration of BPEI, 128 µg/mL, used in fluorescence assays would appear 
to be a lethal concentration as it is greater than the MIC of each isolate. However, an 
important consideration is that generating fluorescent signals above the detection limit 
requires a higher cell density (~ 7 x 109 CFU/mL) than in checkerboard assays (~ 5 x 105 
CFU/mL). Thus, while 128 μg/ml of 600-Da BPEI is lethal in the checkerboard assays, 
is it sublethal in the fluorescence studies. This is shown by measuring cell viability using 
a resazurin cellular metabolism assay. MRSA OU11 was grown until it reached the same 
cell density in H33342 assays (~ 7 x 109 CFU/mL) before BPEI treatment. Resazurin was 
then added and, after 1 hour of incubation, the fluorescence intensity was measured. 
Cellular metabolic product NADH irreversibly reduces resazurin into resorufin, which 
emits strong fluorescence at 580-590 nm, indicating cell viability. As shown in Figure 40, 
MRSA cells were slightly less viable with higher concentrations of 600-Da BPEI, 
suggesting that the membrane remains intact. Previous studies showed that BPEI attached 
to the surface of MRSA cells.68, 119 Additionally, scanning electron micrographs of MRSA 
show that sub-lethal amount of 600-Da BPEI altered the cell wall morphology.1, 68, 119 
These data support a MOA involving the ability of 600-Da BPEI to weaken the cell 
envelope rather than lysing the bacteria. This is a different MOA than that of polymyxin-




Figure 39. H33342 permeation curves show the addition of 128 µg/mL polymyxin B 
(PmB) drastically increases the dye uptake by MRSA OU11, more than twice of that 
128 µg/mL BPEI does. Error bars denote standard deviation (n = 5). 
Using the resazurin assay, corresponding concentrations of polymyxin-B were 
more lethal to MRSA OU11 (Figure 39) than 600-Da BPEI.  In fact, 64 µg/mL of 
polymyxin-B (PmB) caused more cell deaths than 512 µg/mL 600-Da BPEI, and the 
highest concentration of PmB (512 µg/mL) killed the entire MRSA sample. These 
experiments highlight the low antibiotic propensity, but high potentiation ability, of 600-
Da BPEI. These data also support the paradigm that PmB is considered a Gram-negative 
selective drug due to its low MICs (≤ 2 µg/mL), while Gram-positive bacteria require 
much higher concentration of PmB (≥ 32 µg/mL) due to the diffusion barrier imposed by 




Figure 40. Resazurin assay indicates cell viability of MRSA OU11 (at the cell density 
of ~7*109 CFU/mL) treated with either BPEI or polymyxin B (PmB). Resazurin is 
converted to resorufin by cellular metabolism product NADH/H+ and thus provide an 
indication of cell viability. Error bars denote standard deviation (n=8). 
The different MOAs of 600-Da BPEI and PmB can be examined by gauging their 
effect on the influx of H33342. The clinical isolate PA OU19 (Figure 38) and MRSA 
OU11 (Figure 39) were exposed to similar amounts of 600-Da BPEI and PmB. As shown, 
PmB dramatically increased the intracellular concentration of H33342 by disrupting the 
membrane bilayer using its hydrophobic alkyl tail. In contrast, 600-Da BPEI is 
hydrophilic and lacks the energetic driving force to penetrate the membrane. Thus, BPEI 
reduces drug diffusion barriers within the peptidoglycan layer of MRSA and LPS of PA 
without damaging the membrane. This MOA also explains why the rate of H33342 influx 
during the first few minutes is much higher for PmB than 600-Da BPEI. The ability of 
PmB to disrupt membrane layers aligns with the literature precedent that PmB is 
nephrotoxic and neurotoxic towards human cells.154 In contrast, 600-Da BPEI is unlikely 
to damage the membranes45-46, 155 but instead reduces drug-influx barriers that allows 
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faster diffusion through the bacterial membrane that allows enhanced H33342 
accumulation in the MRSA and PA cells. 
The therapeutic potential for 600-Da BPEI is strong and has a foundation in 
previous work of its antibiotic46, 155 and drug-delivery characteristics. First reported in 
1995, large-molecular-weight BPEIs (> 25,000 Da) have strong interactions with lipid 
bilayers and high transfection activity for gene delivery both in vitro and in vivo due to 
high N/P ratios (polycationic nitrogen binding to anionic phosphates in DNA or RNA).43-
44, 156-158 Large BPEIs have higher transfection efficiency than small BPEIs (< 5 kDa). 
Although large PEIs is more beneficial than viral-vectors in gene therapy, larger 
molecular weights correspond to higher cytotoxicity due to more interactions with blood 
components.38-39, 159 Unlike large-molecular-weight BPEIs, 600-Da BPEI is non-
cytotoxic45 and furthermore it lacks the size and high charge ratio of N/P to be an effective 
gene delivery candidate. Unlike polypeptide antibiotics (i.e. polymyxin-B), 600-Da BPEI 
lacks the hydrophobic region necessary to dissolve through the cytoplasmic membrane. 
However, as an antibiotic potentiator, the surface charge of 600-Da BPEI is sufficient to 
attach to anionic teichoic acids of the MRSA cell wall1, 45, 68, 119 and lipid phosphate groups 
of the membrane to create hydrophilic regions for drug intake, which explains its 
antibiotic synergy with erythromycin against the clinical isolates of MRSA. In a similar 
attraction force, 600-Da BPEI binds anionic LPS of P. aeruginosa and thus opens more 
pathways for a co-drug to easily pass through the bacterial membrane.5 Because of this 
new MOA, 600-Da BPEI may have broader applications than originally envisioned.1, 45-




Staphylococci are notorious for their skin and soft-tissue infections that often lead 
to more complicated diseases. Each year, millions of acute skin and soft tissue infections 
(SSTIs) become chronic wound infections.55-58 Instead of taking 3-6 weeks to heal, 
chronic wounds persist for 3-6 months. Delays in healing acute SSTIs are often due to a 
prolonged inflammatory phase of healing caused by bacterial debris, such as 
peptidoglycan from S. aureus, which is a Pathogen-Associated Molecular Pattern 
(PAMP) molecule. Preventing S. aureus peptidoglycan from triggering the release of 
inflammatory cytokines will restore the optimal inflammatory response.160 However, 
successful drugs are elusive because the cell wall debris has a large variation in size and 
shape, making it virtually impossible to target peptidoglycan with monoclonal antibodies 
that recognize specific polysaccharide units. Instead, 600-Da BPEI binds the anionic sites 
of peptidoglycan and prevents the release of cytokines. As shown in Figure 41, S. aureus 
peptidoglycan causes the release of interleukin-8 (IL-8) from primary human epithelial 
keratinocytes (HEKa) cells. IL-8 is a cytokine and chemokine molecule involved with 
neutrophil recruitment to the wound site.161 Its release is stimulated when peptidoglycan 
binds to, and is mainly recognized by, toll-like receptor 2 (TLR2).162-166 In contrast, 600-
Da BPEI does not cause the HEKa cells to release IL-8. However, when 600-Da BPEI 
and S. aureus peptidoglycan are added to HEKa cells, the amount of IL-8 diminishes, 




Figure 41. ELISA assays show the amount of cytokine IL-8 released by human epithelial 
keratinocytes (HEKa cells) in responses to: peptidoglycan (PGN) and 600-Da BPEI (A); 
combinations of PGN and 600-Da BPEI (B). Data are shown as average of triplicate trials. 
Error bars denote standard deviation.   Statistical analysis with the student’s t-test 
generates p-values of < 0.05% (95% confidence, denoted by ∗) and  <0.01 (99% 
confidence, denoted by ∗∗). nd = no statistical difference. 
 
Experts predict that, by 2050, antimicrobial resistance (AMR) will be the 
leading cause of death, claiming 10 million lives a year—a figure that exceeds the 
number of deaths caused by cancer today. A swift global response is required to prevent 
this alarming scenario,7 but pharmaceutical companies are facing significant market 
pressures that hinder their ability to meet this need. The cost of bringing a drug to 
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market is extraordinary, up to a billion dollars, yet there are little or no incentives for 
clinicians to use the new drug. New antibiotics are held in reserve as drugs of last resort 
to prevent the emergence of resistance. Instead, the paradigm of antibiotic potentiators 
has emerged to overcome resistance barriers and restore efficacy to existing antibiotics; 
thereby providing an opportunity to kill drug-resistant and drug-susceptible bacteria 
with the same formulation. However, antibiotic + potentiator combinations are being 
developed against Gram-negative pathogens or Gram-positive pathogens rather than a 
broad-spectrum formulation against both.  
Conclusions 
The data reported demonstrate potentiation of erythromycin against Gram-
positive and Gram-negative pathogens. They provide a better understanding of the 600-
Da BPEI mechanisms of action against multidrug-resistant MRSA and P. aeruginosa 
that may lead to development of broad-spectrum antibiotic and potentiator 
combinations. Antibiotic combination therapy using existing drugs also reserves the 
newer last-resort antibiotics for use against the most serious cases of antibiotic-resistant 
infection. Yet, the need to couple 600-Da BPEI with an antibiotic for effective killing of 
AMR pathogens creates technical hurdles of reducing drug toxicity while matching the 
pharmacokinetics and pharmacodynamics (PK/PD) of the combination. These problems 
are mitigated when the combination is used as a topical agent against wound infections. 
We know that 600-Da BPEI dissolves biofilms1 and expanding the possible classes of 
antibiotics for potentiation that increases therapeutic opportunities. Chronic wound 
infections, those that have not proceeded through a reparative process in three months, 
affect millions of Americans each year55-56 and are often caused by drug resistant 
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bacteria, such as MRSA and MDR-PA. In the absence of a robust pipeline of new 
drugs, existing drugs and regimens have to be re-evaluated as combination(s) with 
potentiators that overcome biofilms and/or antibiotic resistance. Ideally, the potentiator 
should be a single compound with multi-function properties that disable biofilms and 
antibiotic resistance and possibly diminish inflammation. We envision wound treatment 
with antibiotics given topically, orally, or intravenously, and external topical application 
of 600-Da BPEI to disable biofilms, resistance mechanisms, and reduce inflammation. 
This mitigates concerns about toxicity and differences in the PK/PD of antibiotics vs. 
600-Da BPEI. This may improve wound care outcomes by restoring potency to existing 
antibiotics with a single potentiator. Likewise, using an antibiotic potentiator, such as 
600-Da BPEI, to lower the release of cytokines in response to peptidoglycan stimulation 
increases the therapeutic benefit of 600-Da BPEI. Efforts to evaluate the ability of 600-
Da BPEI to modulate cytokine release in response to other PAMPs is currently 
underway. Reducing inflammation helps prevent many acute infections from becoming 
chronic wounds; and lowers the risk of recurrent infection and tissue necrosis.167-168 that 
results in substantial morbidity, disability, hospitalization, and mortality, especially 




Chapter 7: Overcoming multidrug resistance and biofilms of 
Pseudomonas aeruginosa with a single dual-function potentiator 
Background 
Pseudomonas aeruginosa (PA) is a Gram-negative bacterium that often causes 
hospital-acquired infections and cystic fibrosis. PA infections are difficult to treat due to 
their resistance to antibiotics and the ability to form biofilms which result in severe 
chronic infections. Antibiotic resistance in PA is both intrinsic and acquired through 
complex mechanisms and mainly involves barriers from lipopolysaccharide, efflux 
pumps, β-lactamase, and outer membrane porins. It becomes even more challenging for 
clinical management when these bacteria are sequestered in biofilms. These problems 
would be alleviated if, upon the initial presentation of bacterial infection symptoms, 
clinicians were able to administer an antibiotic that kills both susceptible and otherwise 
resistant bacteria; and also eradicates biofilms. As the most common class of antibiotics, 
β-lactams could be used in a new drug if the leading causes of β-lactam antibiotic 
resistance – permeation barriers from lipopolysaccharide (LPS), efflux pumps, and β-
lactamase enzymes – were also defeated. Success may be possible with a discovery 
made in our laboratory. In this study, we demonstrate the ability of 600-Da BPEI to 
overcome multidrug resistance and biofilms of PA in combination with existing 
antibiotics. Mechanisms of action of our technology are also elucidated. It’s important 
to note that this is a large cooperative project that involved the entire lab workforce for 
both data collection and writing the research manuscript. I’m not the sole first-author, 
and my main contribution leads to the data shown here in this chapter. The more 
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detailed and throughout research manuscript is published on ACS Infectious Diseases 
Journal.5 
Pathogeneses and Virulence 
Accounting for around 11-13% of all healthcare-associated infections, PA is 
identified as the second most common cause of hospital-acquired pneumonia. Common 
infections caused by PA include pneumonia, urinary tract infections (UTI), bloodstream 
infections, respiratory tract infections, surgical site/skin infections.170 PA is listed as one 
of the eleven serious threats in the 2019 CDC’s antibiotic resistance threats in the U.S.6 
In pediatric intensive care units (ICUs), PA is the most common cause of hospital-
acquired pneumonia.171 PA infections are associated with high morbidity and mortality, 
especially with immunocompromised patients. In children with cystic fibrosis, 97.5% of 
them are found to be infected with PA by 3 years old.172 Multidrug resistance in PA 
isolates has been emerging in ICUs (resistant to ceftazidime, piperacillin, gentamicin, and 
ciprofloxacin). As a heavy concern in wound healing, PA is prevalent in burn units 
because their biofilms are impenetrable to antibiotics which lead to chronic wound 
infections.173-174 For instance, diabetic wound infections and foot ulcers often become 
chronic because they stall in suboptimal inflammatory phase of healing perpetuated by 
biofilms.169, 175-177 PA infections and their biofilms create serious health issues, and the 
threat to patient survival increases when the bacterium is multidrug resistant P. 
aeruginosa (MDR-PA).178-181 Antibiotic resistance in PA is both intrinsic and acquired 
through complex mechanisms and mainly involves barriers from lipopolysaccharide 
(LPS), efflux pumps, β-lactamase, and outer membrane porins. Biofilms and antibiotic 
resistance create substantial technological hurdles to patient treatment.182 This presents a 
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significant and critical need for way to counteract them. Existing drugs and regimens are 
coupled with potentiators that overcome antibiotic resistance or biofilms.183 However, it 
is possible to develop a single compound that disables biofilms and combats antibiotic 
resistance. As a multi-purpose potentiator, 600-Da branched polyethylenimine (BPEI) 
has the ability to disable resistance and dissolve their biofilms. We have used 600-Da 
BPEI to confront the biofilm directly and disrupt the protective exopolymer substances 
(EPS) network of methicillin-resistant staphylococci while simultaneously counteracting 
β-lactam resistance mechanisms.2, 45, 68, 184 In this report, we show that 600-Da BPEI also 
disables MDR mechanisms, and biofilms, in P. aeruginosa obtained from the American 
Type Culture Collection (ATCC) and antibiotic resistant clinical isolates. 
Purpose of Experiment 
The purpose of this experiment is to investigate the ability of 600-Da BPEI to 
overcome multidrug resistance and biofilms of P. aeruginosa in combination with 
existing antibiotics and to elucidate the treatment’s mechanisms of action. 
Experimental Procedures 
Materials 
In this experiment, the Pseudomonas aeruginosa bacteria were purchased from the 
American Type Culture Collection (ATCC BAA-47 and 27853). Additional MDR-PA 
strains (PA OU1, 12, 15, 19, and 22) were obtained from clinical isolates from the 
University of Oklahoma Health Sciences Center using appropriate IRB protocols and 
procedures. Wild-type P. aeruginosa PAO1 and its efflux pump deficient mutant, PaΔ3, 
were kindly provided by Prof. Helen Zgurskaya, University of Oklahoma. Chemicals 
were purchased from Sigma-Aldrich (DMSO, growth media, and electron microscopy 
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fixatives). Antibiotics were purchased from Gold Biotechnology. 600-Da BPEI was 
purchased from Polysciences, Inc. MBEC™ Biofilm Inoculator with 96-well base plates 
were purchased from Innovotech, Inc.  
Checkerboard Assays and Growth Curves 
Checkerboard assays were followed the methods of Lam et al. to determine the 
synergistic effect between 600-Da BPEI and antibiotics against the P. aeruginosa strains 
growing in cation-adjusted Mueller-Hinton broth (CAMHB).1, 45 Bacterial growth curves 
were obtained using CAMHB media augmented with various amounts of 600-Da BPEI 
and/or piperacillin inoculated with P. aeruginosa BAA-47 cells from an overnight culture 
(5x105 CFU/mL). Cells were grown at 35 °C with shaking. The OD600 (optical density at 
600nm) was monitored and recorded for each sample over 24 hr. Each checkerboard trial 
was done in triplicate. Each growth curve was done in duplicate. 
MBEC Assay:  
The MBEC assay is adapted from previous literature reports.2, 4   
Inoculation and Biofilm Formation: A sub-culture of P. aeruginosa BAA-47 was 
grown from the cryogenic stock on an agar plate overnight at 35 °C. The MBEC plate 
was inoculated with 150 µL of MHB/well plus 1 µL of a stock culture made from 1 
colony/mL of P. aeruginosa BAA-47 in MHB (~5x105 CFU/mL). The MBEC 
inoculator plate was sealed with Parafilm and incubated for 24 hr at 35 °C with 100 rpm 
shaking to facilitate biofilm formation on the prongs. Following biofilm formation, the 
lid of the MBEC inoculator was removed and placed in a rinse plate containing 200 µL 
of sterile PBS for 10 sec.  
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Antimicrobial Challenge: A challenge plate was made in a new pre-sterilized 96-
well plate in a checkerboard-assay pattern to test the synergistic activity of 600-Da BPEI  
+ antibiotic combinations. Antimicrobial solutions were serial-diluted and added to the 
96-well plate, which contained 200 µL of MHB per well. After the rinsing step, the 
preformed biofilm prong lid was immediately transferred into the prepared antimicrobial 
challenge plate and incubated at 35 °C for 20-24 hr.  
Recovery and Quantitative MBEC: After the challenge period, the MBEC 
inoculator lid was washed and transferred into a recovery plate containing 200 µL of 
MHB per well, sonicated on high (Branson B-220, frequency of 40 kHz) for 30 minutes 
to dislodge the biofilm and then incubated at 35 °C for 20-24 hr to allow the surviving 
bacterial cells to grow. After incubation, the OD600 of the recovery plate was measured 
using a Tecan Infinite M20 plate reader to determine the MBEC of the antimicrobial 
compounds tested. A change in OD600 greater than 0.05 indicated positive growth. 
Likewise, the OD600 for the base of the challenge plate was measured to determine the 
MICs of the antimicrobial compounds. The fractional inhibitory concentration index 
(FICI) calculated based on established equation62 was used to determine synergy (FICI ≤ 
0.5), additivity (0.5 < FICI < 1), and no synergy (FICI ≥ 1).  
Scanning Electron Microscopy 
P. aeruginosa BAA-47 cells were inoculated from an overnight culture (5x105 
CFU/mL) and grown at 35 °C with shaking. The bacteria were grown in four separate 
sub-lethal treatments: 600-Da BPEI, piperacillin, combination (600-Da BPEI + 
piperacillin), and untreated control. Growth was stopped at late-lag phase. Samples were 
collected by centrifugation and fixed with Karnovsky fixative (2% glutaraldehyde and 
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2% paraformaldehyde in 0.1M cacodylate buffer) for 30 min. The cells were then fixed 
with 1% OsO4 for 30 min in the dark. The cells were washed with water three times. A 
couple drops of each sample were placed on clean, poly-L-lysine coated coverslips and 
air-dried for 30 min. The samples were dehydrated by going through a series of ethanol 
solutions (20%, 35%, 50%, 70%, and 95%), spending 15 min in each solution. Afterward, 
the samples were dried with hexamethyldisilazane (HMDS). They were then mounted on 
aluminum stubs with carbon tape and sputter-coated with AuPd. A Zeiss NEON SEM 
was used to image the samples at 5 kV accelerating voltage. 
H33342 Bisbenzimide and NPN Accumulation Assays  
Overnight culture of P. aeruginosa BAA-47 was used to inoculate fresh MHB 
media for another 5 hr at 35 °C with shaking. Bacterial cells were collected by 
centrifugation at 6000 rpm for 40 min and resuspended in PBS. The OD600 of the cell 
suspension was adjusted to ~ 1.0 and kept at room temperature during the experiment. 
Aliquots (180 µL/well) of the cell suspension were transferred to a 96-well flat-bottom 
black plate in the format of column 1, PBS blank; column 2, untreated control cells BAA-
47; column 3, cells BAA-47 + BPEI (sub-lethal concentration). Five technical replicates 
of each group were conducted. Fluorescent probes Hoechst 33342 bisbenzimide 
(H33342) or 1-N-phenylnaphthylamine (NPN) was added (20 µL) to each well with a 
final concentration of 5 µM. Fluorescence was read immediately after the addition of 
H33342 or NPN by a Tecan Infinite M20 plate reader with the excitation and emission 
filters of 355 and 460 nm for H33342 or 350 and 420 nm for NPN, respectively. 
Fluorescence data were normalized to the emission before cells were added in the PBS 
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control, and they were plotted against time to show the cellular uptake of H33342 or NPN 
over 10 min. 
Results and Discussion 
BPEI synergizes β-lactams against multidrug-resistant Pseudomonas aeruginosa 
Checkerboard assays demonstrate synergistic effects between 600-Da BPEI and 
β-lactam antibiotics against two laboratory strains of Pseudomonas aeruginosa, ATCC 
27853 and ATCC BAA-47, and several multidrug-resistant (MDR) clinical isolates from 
patients at the University of Oklahoma College of Medicine. The minimum inhibitory 
concentrations (MICs) of 600-Da BPEI and piperacillin against these strains were 
determined and used to calculate the fractional inhibitory concentration index (FICI).1, 68 
An FICI lower than 0.5 indicates synergy while an FICI between 0.5 and 1 represents 
additivity. The 600-Da BPEI MICs against P. aeruginosa ATCC 27853, ATCC BAA-47, 
and 5 clinical isolates varied from 8 to 64 μg/mL (Table 7). For the β-lactam antibiotic 
piperacillin, resistance in P. aeruginosa is defined by USCAST as a minimum inhibitory 
concentration (MIC) ≥ 8 µg/mL.185 As shown in Table 7, the ATCC strains were 
susceptible to piperacillin yet the clinical isolates exhibited strong piperacillin resistance. 
Using checkerboard assays (Figure 42), the presence of 600-Da BPEI lowered the MIC 
of piperacillin against MDR-PA isolate OU1 and the other tested strains (Supporting 




Figure 42. Checkerboard assay data demonstrating that sub-lethal amounts of 600-Da 
BPEI lower the piperacillin MIC against a MDR clinical isolate of P. aeruginosa, OU1. 
The MIC of piperacillin (64 µg/mL) is resistant but 2 µg/mL of 600-Da BPEI (3.3 µM) 
reduces the β-lactam MIC to 4 µg/mL which is interpreted as susceptibility. 
Table 7 data were collected without tazobactam, a β-lactamase inhibitor, 
suggesting that enzymatic activity cannot maintain this form of β-lactam resistance. 
Perhaps the intracellular piperacillin concentration is sufficient to overcome losses from 
β-lactamase hydrolysis. β-lactams are bactericidal antibiotics. Yet, sublethal 
concentrations of piperacillin become bactericidal when combined with sub-lethal 
concentrations of 600-Da BPEI (Figure 43). Within 24 hours, the untreated control group 
grew to an OD600 of 2, as so did the individual treatment of either 600-Da BPEI or 
piperacillin alone, indicating that these concentrations are insufficient to kill the bacteria. 
Only the combination 600-Da BPEI + piperacillin treatment could effectively stop its 




Table 7. MIC and FICI values for P. aeruginosa treated with 600‐Da BPEI, 
piperacillin, and their combination. 
Strain 





1,3 PIP1,3 + 600-Da
 
BPEI   
PA 27853 16 - 4 0.25 + 4 µg/mL 0.31 Synergy 
PA BAA-
47 32 - 4 1 + 8 µg/mL 0.63 Additivity 
PA OU1 16 64 64 4 + 2 µg/mL 0.31 Synergy 
PA OU12 8 128 128 8 + 4 µg/mL 0.31 Synergy 
PA OU15 32 n.d. 128 32 + 8 µg/mL 0.5 Synergy 
PA OU19 64 n.d. > 256 1 + 16 µg/mL 0.31 Synergy 
PA OU22 64 n.d. > 256 4 + 16 µg/mL 0.37 Synergy 
1Piperacillin (PIP) susceptibility breakpoints are resistance ≥ 8 µg/mL; susceptible < 8 µg/mL 
2Determined by the OUHSC Clinical Microbiology laboratory; TAZO = tazobactam  
3Determined in this work; piperacillin only, no tazobactam added; n.d. = not determined 
 
 
Figure 43. Growth curves of PA BAA-47 shows that sub-lethal amounts of 600-Da BPEI 
and piperacillin slow bacterial growth but do not kill the culture. However, treating the 
culture with a combination of 600-Da BPEI and piperacillin, each at sub-lethal 
concentrations, is. Error bars denote standard deviation (n = 2).  
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Mechanisms of action of BPEI on the influx and efflux effects 
As described below, 600-Da BPEI does not inhibit efflux pumps. However, there 
are concentration dependent effects of 600-Da BPEI, which has antibiotic properties at 
high concentration. At lower concentrations used for β-lactam potentiation, the 
mechanism of likely involves disrupting the LPS layer to increase intracellular antibiotic 
concentrations and overcome β-lactamase enzymes and efflux pumps. At slightly higher 
concentrations need to potentiate erythromycin, 600-Da BPEI causes slight perturbations 
to the outer membrane. However, previous data collected with fluorescence microscopy 
show that sub-MIC concentrations of 600-Da BPEI do not accumulate within E. coli 
cells.68 The ability of improve β-lactam efficacy at low concentration occurs because the 
cross-linked network of LPS presents a barrier to free-diffusion of antibiotics. The outer 
membrane of P. aeruginosa contains numerous beta barrel proteins amongst the alkyl 
chains of the phospholipid and LPS leaflets. These porins allow for the diffusion of β-
lactam antibiotics186 between the extracellular milieu and the periplasmic space.187 
However, the inner-core, outer-core, and O-antigen regions of LPS slow the uptake of β-
lactams.188 Ca2+ and Mg2+ ions stabilize these anionic regions and we posit that 600-Da 
BPEI also binds to these sites to cause localized reduction in the diffusion barrier. This 
was evaluated by determining if 600-Da BPEI binds to LPS and by performing 
permeation assays that monitor the intracellular concentration of probe molecules.  
Isothermal Titration Calorimetry (ITC) was used to measure the enthalpy of 
molecular binding interactions between 600-Da BPEI and the LPS isolated from P. 
aeruginosa. An exothermic reaction was found during their titration, indicating an 
electrostatic binding portfolio between cationic BPEI and anionic regions of LPS.5 This 
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binding would cause localized disruption of the LPS-metals network and creates new 
avenues of access for β-lactams to reach porin transporters imbedded in the membrane 
lipid tails. Although 600-Da BPEI may be increasing antibiotic influx, it may also be 
hindering efflux pumps. This can be tested with a fluorescence assay.  Using P. 
aeruginosa PAO1 that is multi-drug resistant,189 bacterial cells were exposed to the 
fluorescent probe H33342 that is also a substrate for efflux pumps. Fluorescence 
spectroscopy data measure its accumulation within the cells (Figure 44). The fluorescence 
intensity of H33342 is significantly enhanced when bound to the cell membranes and 
bacterial DNA, levelling off at the maximum intracellular cellular concentration of 
H33342. The addition of 600-Da BPEI increased its fluorescence intensity four-fold. The 
increase of H33342 intracellular concentration suggests that 600-Da BPEI either 
enhanced the passive diffusion or inactivated the active efflux system. Using PAO1’s 
efflux-deficient mutant, PaΔ3,189 the fluorescence intensity increases further. This shows 
that 600-Da BPEI is not blocking efflux processes. If BPEI was blocking efflux, the 
intensities would be same because the efflux pump target is absent in PaΔ3 cells and 600-
Da BPEI would not influence the intracellular concentration in this mutant strain. 
However, the probe concentration does increase in the presence of 600-Da BPEI and thus 
the effect is attributed to increased drug influx that allows Pseudomonas cells take up 







Figure 44. Effect of 600-Da BPEI on the intracellular accumulation of the DNA-
binding H33342 by P. aeruginosa BAA-47. Real-time kinetics of H33342 uptake show 
that 600-Da BPEI significantly increased the H33342 accumulation (closed red circles) 
into the bacterial cells, compared to the untreated control (open red circles). Similar 
effects are seen with the efflux deficient mutant PaΔ3 (open and closed blue diamonds). 
The intracellular concentration of H33342 in the treated cells is higher than the wild-
type cells indicating that 600-Da BPEI does not hinder efflux processes. Error bars 
denote standard deviation (n = 5). 
 A noteworthy consideration is that the concentration of BPEI (128 µg/mL) used 
in fluorescence assays is higher than those needed for potentiation or MICs because the 
cell density needed for a detectable fluorescence signal was much higher. All 
fluorescence studies used a cell density of ~6x109 CFU/mL, while checkerboard assays 
only inoculated a cell density of 5x105 CFU/mL. Therefore, an amount of 128 µg/mL 
BPEI for fluorescence assays is considered sub-lethal (which is tested and confirmed by 
resazurin assays, Figure 45). The reduction of resazurin to resorufin occurs via cellular 
metabolism and thus is an excellent reporter of cell viability.190 As shown in Figure 45, 
 
125 
128 µg/mL of 600-Da BPEI for this large cell density (~6x109 CFU/mL) is not lethal 
but causes a 12.5% reduction in cell viability. However, resazurin fluorescence values 
for cells treated with polymyxin-B are near background levels indicating that these cells 
are dead. These results have several important impacts. First, the BAA-47 cells in the 
H33342 fluorescence assays are viable and thus drug influx and efflux processes control 
the intracellular concentration rather than widespread disruption of outer membrane that 
leads to cell lysis. Secondly, 600-Da BPEI is less toxic to P. aeruginosa BAA-47 cells 
than polymyxin B that is also toxic toward eukaryotic cells. The biocompatibility of 
600-Da BPEI has been demonstrated against mouse fibroblast cells,68 immortal human 
cell lines,45 and primary human kidney epithelial cells.45 Finally, at sub-lethal 
concentration, 600-Da BPEI is not disrupting cellular energy metabolism because 
resazurin reduction occurs via the conversion of NADH/H+ to NAD+ and thus outer 






Figure 45. Incubation of PA BAA-47 cells at high cell density (~6x109 CFU/mL) with 
resazurin produces the fluorescence molecule resorufin via cellular metabolism. 
Treating these cells with 600-Da BPEI prior to resazurin addition results in lower 
emission that indicates (a) the cells are alive, (b) BPEI has affected the growth rate in a 
concentration-dependent manner, and (c) the cells are not depolarized. This contrasts 
with cells treated with polymyxin-B, which kills the cell culture at all concentrations 
tested. Error bar denotes standard deviation (n = 8). 
 The LPS leaflets are stabilized by electrostatic interactions between their anionic 
sites and metal ions. For instant, Mg2+ ions allow the formation of a stable membrane 
layer by binding to phosphate groups of the lipid A moiety and forming electrostatic 
bridges between adjacent LPS molecules. Additional phosphate and carboxylate groups 
are found on the core oligosaccharides.187-188, 191-192 The o-antigen groups are decorated 
with hydroxyl and the occasional carboxylate groups that can also attract metal ions.192 
These anionic LPS sites are critical resistance mechanisms.141 As Hancock found, 
various compounds (including cationic species), disrupt LPS’s Mg2+ chelation and 
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increase P. aeruginosa’ s susceptibility to antibacterial agents.193-195 The primary 
amines on 600-Da BPEI enable it to bind with phosphate and carboxylate groups, and 
its flexible branches facilitate structural reorganization to reach multiple binding sites 
within the inner- and outer-core regions of LPS, and span adjacent LPS molecules. As a 
consequence, 600-Da BPEI increases the bacterial membrane permeability and allows 
more influx of H33342 (As shown in Figure 44).  
 
Figure 46. The dye 1-N-phenylnaphthylamine (NPN) accumulates in hydrophobic 
regions and fluoresces when bound to phosphate groups. Polymyxin-B (PmB) allows 
greater uptake of NPN than 600-Da BPEI. Error bars denote standard deviation. 
Whether BPEI increases the permeation properties or disrupts the outer 
membrane lipid bilayer, H33342 and resazurin assays cannot answer the question. To 
better elucidate its mode of action, fluorescence probe molecule 1-N-
phenylnaphthylamine (NPN) was used because it localizes to the lipid membrane and 
fluoresces when bound to phospholipids. In the absence of agents that disrupt cell 
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membrane, fluorescence is weak from barriers to passive diffusion. However, then the 
outer membrane is breached, NPN can easily reach phospholipids of the inner leaflet 
and fluorescence intensity increases. As shown in Figure 46, NPN fluorescence reaches 
value of about 13000 units in a sample of ~6x109 CFU/ml P. aeruginosa BAA-47 cells. 
Treating a similar sample with 64 µg/mL of polymyxin-B causes a 2.7 fold increase in 
fluorescence intensity, which occurs via insertion of polymyxin-B into the membrane 
via self-promoted uptake.193 However, 64 and 128 µg/mL of 600-Da BPEI cause a 1.5 
fold increase in NPN fluorescence and we know that these concentrations of 600-Da 
BPEI are non-lethal (Figure 45). Thus, we suggest that 600-Da BPEI is weakening the 
LPS diffusion barrier, but it is not intercalating into the membrane bilayer that 
otherwise would lead to a higher increase in NPN fluorescence intensity. 
SEM images demonstrate adverse effects of 600-Da BPEI on morphology 
The ability of 600-Da BPEI to weaken the LPS diffusion barrier without causing 
widespread membrane disruption and cell lysis is shown with scanning electron 
microscopy (SEM). SEM was conducted to examine morphology and the possible effects 
of 600-Da BPEI on bacterial cell division. P. aeruginosa BAA-47 cells were grown to 
mid-log phase and subjected to four separate treatments: untreated control, sublethal 600-
Da BPEI, sub-lethal piperacillin, and combination of 600-Da BPEI and piperacillin, each 
at sub-lethal combinations. SEM images of the untreated control sample (Figure 47A) 
show that all the cells have regular rod-shape with a normal size distribution and division 
septa are clear. BPEI treated cells (Figure 47B) are longer and cell-division septa show a 
gradual narrowing rather than a sharper interface. The piperacillin treated cells (Figure 
47C) are longer, do have signs of a well-form division septum, and exhibit signs of cell 
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wall weakening without bursting. Combination of BPEI + piperacillin caused the treated 
cells (Figure 47D) to rupture (Figure 47E) and show extreme distortions in shape (Figure 
47F). The extreme distortions both in size (~20 times longer than untreated control cells) 
and shape without obvious division septa suggests that the cell envelope is damaged and 
that recruiting, activity, and/or competence of bacterial divisome196-197 components is 
hindered. These cellular morphological changes and cell wall weakening aid in 
explaining the bactericidal properties of the BPEI + piperacillin combination when the 





Figure 47. Scanning electron micrograph images of PA BAA-47. Untreated control 
cells appear with regular rod-shape of about 2-3 µm long (A). 600-Da BPEI treated 
cells (B) and piperacillin treated cells (C) show inconsistency in their size with longer 
lengths but the rod-shape remains. Combination of 600-Da BPEI + piperacillin treated 
cells (D) show extreme distortions both in size and shape with insets (E) and (F) for 
higher magnifications.  Scale bars = 2µm. 
 
131 
Eradicating P. aeruginosa biofilms 
Biofilms are accumulations of microorganisms embedded in a polysaccharide 
matrix known as extracellular polymeric substance (EPS), which protects the bacteria 
from antimicrobial agents.169, 177 Current in-patient treatments include cleansing the 
wound, debridement, maintaining a moist tissue environment, and – when possible – 
eliminating the underlying factors that contributed to poor wound healing.131 BPEI 
confronts the biofilm directly by disrupting the protective EPS. As shown in Figure 48, 
biofilms of P. aeruginosa BAA-47 create additional barriers that require 256 µg/mL of 
piperacillin to kill the bacteria. This minimum biofilm eradication concentration (MBEC) 
is significantly higher than the MIC of 4 µg/mL. Likewise, the MBEC of 600-Da BPEI 
is 512 µg/mL, compared to its MIC of 32 µg/mL. A combination treatment results in 
biofilm eradication with 16 µg/mL of BPEI and 8 µg/mL of piperacillin. As with the 
planktonic checkerboard assays, this data was collected without a β-lactamase inhibitor. 
The mechanism of action for disrupting the biofilm relies on the ability of cationic 600-
Da BPEI to interact with anionic targets. Instead of binding with LPS in the planktonic 
cells, the biofilm targets are extracellular DNA, anionic polysaccharide Psl, and anionic 
polysaccharide alginic acid.31, 65-67, 112-118 The presence of the cationic polysaccharide Pel 
in P. aeruginosa biofilms would repel BPEI, but this affect does not prevent 600-Da BPEI 
from disrupting the biofilm matrix and thus piperacillin can access to the underlying cells. 
The data in Figure 44 also confirms the paradigm that antibiotics effective against 
planktonic P. aeruginosa are nearly inert against biofilms and resistant strains. when 600-
Da BPEI binds to EPS, the biofilm disperses because the intermolecular network of 
exopolymers, protein, and metals ions is disrupted.2 As a result, quiescent bacteria are 
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released into solution where they become metabolically active and thus the antibiotic can 
kill the bacteria when additional BPEI molecules reduce LPS barriers to drug influx. 
 
Figure 48. Biofilm eradication assay data using collected with the Calgary biofilm 
device. EPS creates additional barriers to piperacillin efficacy and thus 256 µg/mL are 
required to kill the bacteria. However, 600-Da BPEI disrupts the biofilm EPS and 
increases β-lactam access to the cells, reducing the MBEC to 8 µg/mL. 
Conclusions 
 Multidrug resistance and biofilms of Pseudomonas aeruginosa were defeated by 
combination antibiotic therapy: existing β-lactam + 600-Da BPEI. Potentials of BPEI as 
a potentiator have shown to exceed what originally thought of only working against 
Gram-positive pathogens. Here, 600-Da BPEI targets LPS-mediated resistance in 
MDR-PA and restores piperacillin efficacy without the need for β-lactamase inhibitors. 
Additionally, 600-Da BPEI is attracted to anionic components of the bacterial biofilm, 
resulting in disruption of the extracellular matrix that dissolves the biofilms to enable 
anti-biofilm activity of piperacillin. Thus, 600-Da BPEI may improve patient care 
outcomes by restoring potency to existing antibiotics with a single potentiator. An 
advantage of 600-Da BPEI is that it does not need to cross the membrane itself to be 
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effective. By targeting the anionic inner-core and outer-core polysaccharides141, 198 and 
biofilm EPS, 600-Da BPEI creates new avenues of access for antibiotics to reach their 
targets, Therefore, BPEI does not have to traverse the membrane for potentiation. This 
contrasts with other cationic antimicrobial agents, such as cationic peptides, 
aminoglycosides, and polymyxins, whose hydrophobic properties are required for 
membrane disruption. Its mechanisms of action on P. aeruginosa have been examined 
and documented to provide a strong foundation of understanding for future drug design 
and development.  
Despite their tiny size, each pathogenic microorganism has an exquisite 
mechanism to survive, infect, and reproduce. For centuries, we coexist. Diseases are 
inevitable. Whether it’s a virulent strain of P. aeruginosa or an opportunistic S. 
epidermidis, we never know when these bacteria would gene-transfer or mutate into a 
deadly one. The best way to mitigate is to study and research—an art that saves lives. 
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